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GLOBAL ABSTRACT
The cholesterol metabolites known as oxysterols play an important role in
maintaining cell homeostasis. They play vital roles in inflammation, cell growth,
cell signaling, immunity, oxidative stress and aging. Following the discovery that
the most abundant oxysterol, 27-hydroxycholesterol (27-OHC) is a Selective
Estrogen Receptor Modulator (SERM), it has been implicated in hormonal
cancers such as breast and uterine cancer. 27-OHC is a ligand of estrogen
receptors (ER), a nuclear hormone receptor involved in cell growth and
proliferation. The downstream events followed by 27-OHC-induced ER activation
in the context of breast cancer is unknown. Also, the role of 27-OHC in prostate
cancer is ill-defined given the involvement of ER in prostate cancer (PCa) and
benign prostatic hyperplasia (BPH). Our studies delineate for the first time a
potential cellular mechanism of action of 27-OHC in the context of ER+ breast
cancer, whereby 27-OHC induced ER activation in ER+ MCF7 cells increases
cell proliferation via perturbing the p53-MDM2 axis. We demonstrate that 27OHC, through ER, exacerbated p53 inactivation via MDM2 resulting in an
increase in cell proliferation in ER+ breast cancer cells. Next, we address the
possibility of 27-OHC exacerbating prostate cancer cell proliferation. In the
context of BPH and PCa, we show that 27-OHC not only increased cell
proliferation in tumorigenic cell lines, LNCaP and PC3 but also in the nontumorigenic cells, RWPE-1. We further demonstrate that 27-OHC- induced cell
xii

proliferation in prostate cells is specifically through ERβ. Given the tissue
dependent selective ER modulation of 27-OHC, our novel findings suggest that
27-OHC activates ER signaling in the prostate. Altogether, our findings elucidate
and establish the novel role and cellular mechanism of action of the oxysterol 27OHC in the context of breast and prostate cancer. In the interest of discovering
new therapeutic avenues for breast and prostate cancers, our work may aid in
the development of novel therapies that could mitigate/halt/alleviate the
progression of ER+ breast cancers and prostate cancers.

xiii

CHAPTER I
INTRODUCTION
Oxysterols: The Arcane Derivatives of Cholesterol
Cholesterol is a critical component of the cell membranes of the cells. It
helps to preserve the fluidity of the cell membranes which is vital to maintain cell
homeostasis (Róg and Vattulainen 2014). Two thirds of cholesterol in our bodies
are synthesized de novo, while the rest is acquired through dietary
sources(Dietschy 1984).
Cholesterol is synthesized de novo in the following steps; first, acetyl CoA
is converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). Second, HMGCoA
is converted to mevalonate by the rate limiting enzyme, 3-hydroxy-3methylglutaryl-CoA reductase (HMGCoA reductase). Third, mevalonate is
converted to an isoprene based compound, isopentenyl pyrophosphate (IPP)
which is later transformed into squalene. Lastly, following a series of reactions,
squalene is converted to cholesterol which eventually becomes vital precursor of
vitamin D, all steroids and bile salts (Singh et al. 2013; Di Ciaula et al. 2014; King
2016) (Fig.1).
Cholesterol regulation is important to cell survival. Cholesterol can be
regulated by the rate limiting HMGCoA reductase enzyme, regulation of the
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amount of intracellular free cholesterol by sterol O-acyl transferases (SOAT1 and
SOAT2) and regulation of plasma cholesterol levels via Low Density Lipoprotein
(LDL) receptor facilitated uptake and High Density Lipoprotein(HDL) reverse
transport (Goedeke and Fernández-Hernando 2012; van der Wulp et al. 2013;
King 2016). Close observation and regulation of the plasma cholesterol (including
HDL and LDL fractions) is the most common physiological indicator that
clinicians use to diagnose and curb hypercholesterolemia in patients (Grundy
and Bilheimer 1989; Guven et al. 2006; Sonmez et al. 2015).

2

Figure 1: A diagram of the cholesterol biosynthetic pathway. Acetyl CoA
converted to HMG CoA which, through a series of reactions leads to the
synthesis of cholesterol which is a precursor to bile salts, vitamin D and steroids
(reproduced from King 2016).
In addition to being a precursor to steroid hormones (Gabitova et al.
2013), bile acid and vitamin D (Berg et al. 2002), cholesterol is a precursor (as
cholesterol continues to exist even after oxidations to oxysterols) to a family of
steroid-like compounds called oxysterols. Oxysterols are oxidized cholesterol
metabolites which have various signaling consequences in inflammation,
immunity, cellular signaling, lipid metabolism, development and apoptosis (Brown
and Jessup 1999; Björkhem 2002; Javitt 2008; Sato 2010; Vesa M Olkkonen et
al. 2012; Björkhem 2013).
Oxysterols are a 27-carbon compound with a cholesterol like backbone
containing either an epoxide or ketone or an additional hydroxyl group in the
sterol center and/or a hydroxyl group in the side chain (Vurusaner et al. 2016
Mar) (Fig 2).
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Figure 2: Structure of cholesterol and its main oxidation sites in red. (reproduced
from Vurusaner et al. 2016 Mar)
Oxysterols are synthesized by autoxidation or by a specific
monooxygenase secondary to enzymatic/non-enzymatic lipid peroxidation. There
are several oxysterols generated via cholesterols including but not limited to: 7hydroepoxycholesterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol, 7oxocholesterol, cholesterol 5α,6α-epoxide, cholesterol-5β,6β-epoxide, 4βhydroxycholesterol, cholestane-3β,5α,6β-triol, 27-hydroxycholesterol, 25hydroxycholesterol, 24S-hydroxycholesterol, 24,25-epoxycholesterol and so forth
(Björkhem and Diczfalusy 2002).
The most abundant oxysterol in the brain is 24S-hydroxycholesterol (24SOHC) while 27 hydroxycholesterol (27-OHC) is predominantly found in the
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periphery (Burkard et al. 2007a; Ramirez et al. 2008; Rantham Prabhakara et al.
2008; Hirayama et al. 2009; Björkhem et al. 2013; Bandaru and Haughey 2014).
These two oxysterol have been implicated in numerous diseases, particularly in
neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease
(Rantham Prabhakara et al. 2008; Dasari et al. 2010; Marwarha et al. 2011;
Bandaru and Haughey 2014; Marwarha and Ghribi 2015).

Figure 3: A schematic diagram depicting the biosynthesis of the major oxysterols.
The enzymatically derived products are indicated in green, cholesterol
metabolites derived from autoxidation with red, and yields derived from shunt
of the cholesterol biosynthetic process in blue (reproduced from Olkkonen et
al., 2012).
5

In this dissertation, I will focus on the role of the most abundant oxysterol
in the plasma, 27-OHC, in breast and prostate cancers. 27-OHC has been
implicated to play significant role in inflammation (Umetani et al. 2014),
Alzheimer’s disease (Marwarha and Ghribi 2015), Parkinson’s disease (Björkhem
et al. 2013) and atherosclerosis (Umetani et al. 2007a; Karuna et al. 2011). In
this disquisition, I will introduce my findings to establish the newly characterized
deleterious role of 27-OHC in hormone-dependent cancers of the breast and
prostate.
Breast Cancer
Breast cancer is the most common cancer amongst American women,
with one in every eight women developing this disease (Gonzalez-Angulo et al.
2007). The etiology of breast cancer appear to be multi-factorial, including
environmental agents and genetic susceptibilities playing a role in the
pathophysiology of this disease.
ER alpha and its hormonal ligand, estradiol play a significant role in the
development and progression of ER-positive breast cancers (Doisneau-Sixou et
al. 2003; Arpino et al. 2005; Bailey et al. 2012; Coates et al. 2012; Renoir et al.
2012) which account for 70% of all breast cancers (Harrell et al. 2006). There are
multiple risk factors associated with breast cancer, including
hypercholesterolemia (Printz 2014), obesity (James et al. 2015), Type 2 diabetes
(Crujeiras et al. 2013) and hormone dyshomeostases (Jankowitz and Davidson
2013; Bodicoat et al. 2014).
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Breast cancer develops when the normal breast epithelium transforms
into atypical breast hyperplasia, ductal carcinoma in situ, invasive ductal
carcinoma and eventually a metastatic cancer (Fig. 4). Molecular events leading
to the progression at each step of this debilitating disease are yet to be
determined, however it is hypothesized that steroidal hormones and their
receptors play a vital role in this disease (Rivenbark et al. 2013).

Figure 4: A schematic diagram displaying the canonical progression of breast
cancer pathology (reproduced from Gómez-Suaga et al. 2014)
Breast cancers are classified based on patterns of gene expression in the
corresponding subtypes. Molecular subtypes have been developed primarily
based on five major biomarkers found in the breast tissue: ER, progesterone
receptor (PR), human epidermal growth factor receptor 2 (HER2), cytokeratin 5/6
and human epidermal growth factor receptor 1 (HER1). ER+ breast cancers are
7

sub-classified as luminal A or Luminal B. Luminal A subtype expresses
ER+/PR+/HER2- , while luminal B expresses ER+/PR+/HER2+. Likewise, nonluminal or ER- breast cancers, are subclassified as either HER2+ i.e ER-/PR/HER2+ or HER2-, ER-/PR-/HER2-, which is also known as triple negative breast
cancer (TNBC) (Fig. 5). Additionally, basal like breast cancers can be identified
using the remaining markers: cytokeratin 5/6 and HER1. This method of
molecular classification of breast cancer subtypes does not encompass all
clinically diagnosed breast cancer cases, however it comprises of most of the
breast cancers diagnosed and potentially determines the hormone dependence
(or lack thereof) of the breast cancer tumor based on its receptor status
(Rivenbark et al. 2013). Other types of breast cancers include HER2 enriched
and Claudin-low breast cancers (Prat et al. 2011; Cancer Genome Atlas Network
2012). Patients with ER+ breast cancers are usually treated with anti-estrogens
such as tamoxifen, while those with ER- breast cancers are treated with
alternative approaches based on HER2 receptor status; for instance,
trastuzumab (anti-HER2 drug) to target HER2+ non-luminal breast cancers (Ali
and Coombes 2000; Sørlie et al. 2001; Buzdar 2004; Rivenbark et al. 2013).
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Figure 5: A diagram depicting the classification of all breast cancers based on
available immunohistochemistry marker profiles (reproduced from Blows et al.
2010).
ER signaling pathways can be affected by the abundance of estrogens
and estrogen like molecules in the body, diet and/or the environment.
Uncontrolled ER activation can also occur due to mutations and epigenetic
events leading to the development of atypical breast hyperplasia subsequently
ER+ breast cancer (Kun et al. 2003; Renoir et al. 2012; Rivenbark et al. 2013).
Currently, for ER+ breast cancers, hormone therapy is the frontline
therapeutic avenue utilized by clinicians to combat ER+ breast cancer tumor
growth (Baum et al. 2002a; McKeage et al. 2004; Renoir et al. 2012). There are 2
distinct ways by which hormone therapy works: by directly blocking estrogens
and estrogen like molecules using competitive ER antagonists and by reducing
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the bioavailability of estrogens through inhibiting their biosynthesis via aromatase
inhibitors. While both strategies are effective, there is a concern of ER+ breast
cancer cells being ‘desensitized’ and becoming less dependent on estrogens for
tumor growth. It is well known that patients often develop resistance to hormone
therapy during the course of their treatment and require a combination of
alternative therapies (including radiotherapy) to effectively curb ER+ tumor
growth and/or metastasis (Hasson et al. 2013; Hart et al. 2015).
The cholesterol metabolite 27-OHC, binds to estrogen receptor (ER) and
elicits ER signaling. 27-OHC is characterized as a Selective Estrogen Receptor
Modulator (SERM) and provokes ER activation in the breast, several lines of
evidence have suggested its deleterious role in ER+ breast cancer progression
(Cruz, Torres, María Eugenia Ramírez, et al. 2010; Umetani and Shaul 2011;
Nelson et al. 2013; Wu et al. 2013; Raza et al. 2015). 27-OHC not only increased
the proliferation of breast cancer cells in vitro (Cruz, Torres, María Eugenia
Ramírez, et al. 2010; Nelson et al. 2013; Singh et al. 2013; Wu et al. 2013; Raza
et al. 2015), but also increased tumor growth in CYP7B1−/−/MMTV-PyMT mice,
with high levels of 27-OHC. The increased tumor growth was rescued in these
mice by the administration of an ER- specific inhibitor, fulvestrant(Nelson et al.
2013). Also, 27-OHC content in ER+ breast cancer tissue is higher when
compared to normal breast tissue from breast cancer patients (Wu et al. 2013).
These studies underline the importance of 27-OHC induced ER activation in ER+
breast cancer tumor growth.
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In this document, we will discuss the role of 27-OHC in ER+ breast cancer
cell proliferation and delineate a potential cellular mechanism of action of 27OHC and its impact on the p53-MDM2 axis in the context of ER+ breast cancers.
Prostate Cancer
Every year almost 230,000 men are diagnosed with prostate cancer.
Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) predominantly
occur in older men (Chodak 2006; Dhingra and Bhagwat 2011). The etiology of
PCa and BPH appear to be multifactorial with age as the most commonly
identified major risk factor (Gann 2002; Chokkalingam et al. 2003; William G.
Nelson, M.D., Ph.D., Angelo M. De Marzo, M.D., Ph.D., and William B. Isaacs
2003; Bostwick et al. 2004). Other risk factors that contribute to PCa and BPH
include oxidative stress (Khandrika et al. 2009), hypercholesterolemia (Moon et
al. 2015) and obesity (Burton et al. 2010).
PCa which affects one in every six men in the US, is an ailment that leads
to the enlargement of the prostate due to the presence of cancer cells that could
metastasize to the bone or the lymph nodes (Sato et al. 1997). On the other
hand, BPH is the enlargement of the prostate due to hyperplasia of the prostatic
stroma and/or glandular elements. In PCa, the prostate enlargement is not only
due to the hyperplasia of stromal cells but also the prostatic epithelial cells.
However, PCa and BPH, both have symptoms that overlap each other making it
difficult during diagnosis, especially during early stages of PCa (Chokkalingam et
al. 2003; Shukla et al. 2016).
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PCa and BPH share risk factors associated with them (Fig. 6). However,
the relationship between the two is yet to be elucidated. There are two schools of
thought, with one claiming PCa and BPH as two separate disorders while the
other believes that BPH is a condition that precedes and eventually leads to PCa
development (Ørsted and Bojesen 2013). According to the latest and only
systematic review to date, which examined 16 case-control studies and 10 cohort
studies, patients with BPH have ~2.9 fold increased incidence of PCa (Dai et al.
2016). However, there is currently little to no evidence to suggest that BPH
always progresses to PCa. While both conditions have shared risk factors, some
risk factors may favor the transformation of BPH to PCa. For instance,
inflammation is a risk factor for BPH and PCa, however some studies have
established that BPH tissues with inflammatory infiltrates were more likely to
advance to PCa than those without inflammation (Higgins and Thompson 2002;
Guyatt et al. 2008).
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Figure 6: A pictorial diagram depicting the difference and shared risks between
BPH and PCa (reproduced from Ørsted and Bojesen 2013).
Urologists currently distinguish between BPH and PCa using a biomarker
such as prostate specific antigen (PSA) and histological examination of prostatic
tissue. PSA levels are much higher in PCa patients versus BPH patients and
presence of pre-cancerous lesions in prostatic biopsies indicate PCa while the
absence of it indicates BPH (Geybels et al. 2013; Shukla et al. 2016) (Fig. 7).
More non-invasive biomarkers are being identified to better distinguish between
PCa and BPH: novel biomarkers include β-2 microglobulin(β2M), pepsinogen 3,
group 1 (PGA3) and mucin 3 (MUC3) in the urine (Jedinak et al. 2015).
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Figure 7: Histopathology of biopsy specimen. Prostate biopsy specimen: (A–C)
Adenocarcinoma (magnification, ×100), (D) benign prostate (glandular)
hyperplasia and (E) non-lesion area. (hematoxylin and eosin stain; scale bars,
100 μm) (reproduced from Miyazawa et al. 2014)
PCa is an ailment that morphs as it goes through 4 stages of
development. The first 2 stages (T1 and T2) include a confined tumor in the
prostate. At stage 3 (T3), the tumor invades the seminal vesicles and at stage 4
(T4) the tumor metastasizes to adjacent structures such as the lymph nodes and
the bones (Kaarbø et al. 2007) (Fig. 8).
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Figure 8: Stages of PCa and possible treatment regimens at various stages of
the disease (reproduced from Garnick and Fair 1998)
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Cholesterol involvement in prostate cancer has been suspected for over a
century when it was found to accumulate in prostate cancer tissues (White 1909).
More recent studies also demonstrate a positive correlation between high plasma
cholesterol and high-grade prostate cancers (Mondul et al. 2010). Diets rich in
cholesterol have also been shown to induce metastasis in prostate cancer(Moon
et al. 2015). However, statins, a class of drugs which competitively inhibit 3hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCoA reductase), a key
enzyme in cholesterol synthesis pathway, is unable to rescue or predict
prognosis of patients with PCa (Geybels et al. 2013; Algotar et al. 2014; Kantor
et al. 2015).
The impact of cholesterol in prostate cancer may be through its oxidized
metabolite, 27-OHC. Levels of 27-OHC increase with age, oxidative stress, and
hypercholesterolemia (Hirayama et al. 2009; Dasari et al. 2010; Prasanthi et al.
2011; Nelson et al. 2013). These factors are all suspected to increase the risk of
developing PCa and BPH. In this thesis, I will also discuss the potential role of
27-OHC in prostate cancer cell proliferation.

16

CHAPTER II
ROLE OF 27-HYDROXYCHOLESTEROL IN BREAST CANCER
27-hydroxycholesterol Regulates p53 activity and Increases Cell
Proliferation via MDM2 in Breast Cancer Cells.
Abstract
Estrogen is synthesized from cholesterol and high cholesterol levels are
suggested to be associated with increased risk of estrogen receptor(ER)-positive
breast cancer. The cholesterol metabolite 27-hydroxycholesterol (27-OHC) was
recently identified as a selective estrogen receptor modulator (SERM) and has
been shown to impact breast cancer progression. However, the mechanisms by
which 27-OHC may contribute to breast cancer are not all known. We determined
the extent to which 27-OHC regulates cell proliferation in MCF7 ER positive
breast cancer cell line involving the tumor suppressor protein p53. We found that
treatment of MCF7 cells with 27-OHC reduced p53 transcriptional activity.
Conversely, treatment of the ER negative MDA MB 231 cells with 27-OHC
induced no change in p53 activity. Exposure of MCF7 cells to 27-OHC was
associated with increased protein levels of the E3 ubiquitin protein ligase MDM2
and decreased levels of p53. Moreover, 27-OHC also enhanced physical
interaction between p53 and MDM2. Furthermore, 27-OHC induced proliferation
was attenuated using either the p53 activator Tenovin-1 or
17

the MDM2 inhibitor Nutlin-3 and Mdm2 siRNA. Taken together, our results
indicate that 27-OHC may contribute to ER positive breast cancer progression by
disrupting constitutive p53 signaling in an MDM2 dependent manner.
Introduction
Breast cancer is the most common cancer amongst American women,
with one in every eight women developing this disease (Gonzalez-Angulo et al.
2007). The causes of breast cancer are multi-factorial, including environmental
agents and genetic susceptibilities. ER alpha and its agonists, estradiol (and
estradiol-like compounds), play a significant role in the progression of ERpositive breast cancer forms. Several therapeutic strategies have been
developed against ER, however a significant number of ER-positive breast
carcinoma patients experience drug resistance (Baum et al. 2002b; Buzdar 2004;
Franco et al. 2004).
27-OHC has been characterized as an endogenous ligand for ER
(Umetani and Shaul 2011; Nelson et al. 2013; Wu et al. 2013). 27-OHC is an
oxysterol formed from cholesterol through the enzyme CYP27A1. This oxysterol
is the most abundant cholesterol metabolite in plasma, and also accumulates in
macrophages. In vitro, 27-OHC elicits a signaling response via ER at
concentrations as low as 0.1µM (Wu et al. 2013). In the plasma of healthy human
subjects, 27-OHC is found at concentrations of 0.2-0.6µM, and these
concentrations can increase dramatically under conditions such as
hypercholesterolemia (Duane and Javitt 1999). Thus, fluctuations in 27-OHC
may modulate ER and potentially contribute to the pathogenesis of ER+ breast
18

cancers. While it has been established that 27-OHC is an endogenous selective
ER modulator (SERM) and that it exacerbates breast cancer pathophysiology
(DuSell et al. 2008; Cruz, Torres, María Eugenia Ramírez, et al. 2010; Nelson et
al. 2013), its role in molecular events following ER activation in the context of
breast cancer pathogenesis is not fully understood.
The tumor suppressor protein, p53 plays an important role in apoptosis,
cell cycle and senescence. Under normal conditions, wild type p53 is in “stand
by” mode. Under genotoxic stress, p53 is activated to prevent anomalous cell
proliferation and neoplastic development. Hence, p53 has been extensively
studied as an anticancer target and as a cancer prognostic tool to diagnose and
treat several types of cancers (Pharoah et al. 1999; van der Burg et al. 2001;
Miller et al. 2005; Coates et al. 2012; Walerych et al. 2012; Ahn et al. 2013; Khoo
et al. 2014). Levels of p53 are regulated by the E3 ubiquitin ligase, Mouse
Double Minute 2 protein (MDM2). MDM2 tags p53 to undergo ubiquitination and
subsequently proteasomal degradation (Moll and Petrenko 2003; Manfredi 2010;
Dolfi et al. 2014). In this report, we determined the effects of 27-OHC on cell
proliferation in the context of p53 and MDM2 regulation. We found that 27-OHC
via ER inhibits p53 transcriptional activity in an MDM2 dependent manner,
resulting in cell proliferation.
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Methods
Reagents
27-OHC was purchased from Santa Cruz Biotechnologies (Santa Cruz, CA), the
p53 activator, tenovin-1 from Tocris Bioscience (Ellisville, MO), Nutlin-3 and
Fulvestrant from Cayman Chemicals (Ann Arbor, MI), the reporter constructs
encoding p53 response elements conjugated to the firefly luciferase gene from
SA Biosciences (Frederick, MD) and β-estradiol from Sigma-Aldrich (St. Louis,
MO). All cell culture reagents, with the exception of fetal bovine serum (Atlanta
Biologicals, Lawrenceville, GA) were from Invitrogen (Carlsbad, CA). Human
MCF7 and MDA MB 231 cell lines were purchased from ATCC (Manassas, VA).
Cell Culture
The human ER-positive breast cancer cells MCF7 and ER-negative breast
cancer cells MDA MB 231 were grown in phenol red free DMEM/F12 medium
containing 10% charcoal dextran stripped fetal bovine serum (FBS) and 1%
antibiotic/antimycotic mix. Cells were maintained at 37°C in a saturated humidity
atmosphere containing 95% air and 5% CO2.
Cell Proliferation Assays
Proliferation assays were conducted on black 96 well plates using CyQUANT
Direct Cell Proliferation Assay purchased from Invitrogen (Carlsbad, CA), which
quantifies cell number using DNA content and membrane integrity. Cells were
processed for proliferation as per manufacturer’s protocol and read using Spectra
MAX GEMINI EM (Molecular Devices).
20

Dual Luciferase Assays
Dual Luciferase Reporter Assay System (Promega; Madison, WI) was used to
determine the effect of 27-OHC on p53 activity. MCF7 and MDA-MB-231cells
were incubated for 18 hours with transfection ready p53 response element
conjugated with firefly luciferase construct and constitutively expressing Renilla
Luciferase construct (SA biosciences; Valencia, CA) using Lipofectamine 2000
(Invitrogen; Carlsbad, CA) as per the manufacturer’s recommendations. Firefly
luciferase readings were normalized against constitutive Renilla luciferase
readings.
Western Blot Analysis
Treated MCF7 cells were washed with PBS, trypsinized and centrifuged at 5000
g. The pellets were washed with PBS and homogenized in M-PER tissue protein
extraction reagent (Thermo Scientific; Waltham, MA) supplemented with
protease and phosphatase inhibitors. Denatured proteins (5 µg) were separated
in 10% or 12.5% SDS-PAGE gels, transferred to a PVDF membrane (Millipore;
Billerica, MA) and incubated with antibodies to p53 (1:1000, Thermo Scientific;
Waltham, MA) or MDM2 (1:1000, Santa Cruz; Dallas, TX). β-actin was used as a
gel loading control for the whole cell homogenates. The blots were developed
with enhanced chemiluminescence (ECL Clarity kit, Bio-Rad; Hercules, CA).
Bands were visualized on a PVDF membrane and analyzed by LabWorks 4.5
software on a UVP Bioimaging System (Upland, CA). Quantification of results
was performed by densitometry and the results analyzed as total integrated
densitometric values (arbitrary units).
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Co-Immunoprecipitation
Co-Immunoprecipitation (Co-IP) in cell homogenates was performed for p53 and
MDM2 using “Catch and Release” immunoprecipitation kit (Millipore; Billerica,
MA) according to the manufacturer's protocol. Briefly, 3×10 6 MCF7 cells were
homogenized in Mammalian Protein Extraction Reagent (MPER) supplemented
with protease and phosphatase inhibitors (Thermo Scientific; Waltham, MA). The
homogenates containing the equivalent to 500μg of total protein content were
incubated with 2μg of p53 mouse antibody (1:1000; Thermo Scientific; Waltham,
MA) or 2μg of MDM2 mouse antibody (1:1000; Santa Cruz; Dallas, TX) overnight
in the spin columns followed by elution. Eluate from p53 antibody precipitated
protein-antibody complex (5µL) was resolved on a SDS-PAGE gel transferre onto
a polyvinylidene difluoride (PVDF) membrane (BioRad; Hercules, CA) and
incubated with MDM2 antibody followed by development with enhanced
chemiluminescence ECL clarity (Bio-Rad; Hercules, CA). Analogously, eluate
from anti-MDM2 antibody precipitated protein-antibody complex (5µL) was
resolved on a SDS-PAGE gel transferred onto a PVDF membrane and incubated
with p53 antibody followed by development with enhanced chemiluminescence
ECL clarity. Bands were visualized on a PVDF membrane and analyzed by
LabWorks 4.5 software on a UVP Bioimaging System.
Double Immunofluorescence Staining
Coverslip seeded cells were rinsed with PBS and fixed in cold acetone, blocked
with 10% normal goat serum and incubated overnight at 4˚C with p53 antibody
(anti-rabbit) and MDM2 antibody (anti-mouse). p53 was conjugated to Texas Red
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and MDM2 to Alexa Fluor 488. All coverslips were washed and mounted with
Vectashield containing DAPI and visualized with a Zeiss LSM 510 META
confocal system coupled to a Zeiss Axiophot 200 inverted epifluorescence
microscope (Carl Zeiss Microscopy; Dublin, CA). Quantification of percent
overlap was determined using MetaMorph Microscopy Automation and Image
Analysis Software (Molecular Devices).
Small Interfering RNA
The cells were transfected with MDM2 siRNA using Lipofectamine 2000
(Invitrogen; Carlsbad, CA) and incubated for 48 hours, followed by their
respective treatments. Control (scrambled) siRNA were obtained from Santa
Cruz Biotechnologies (sc-37007; Dallas, TX) . The siRNA to MDM2 sense and
antisense strands were: GCUUCGGAACAAGAGACCC and
GGGUCUCUUGUUCCGAAGC (Santa Cruz; Dallas, TX).
Statistical Analysis
All the assays were carried out in triplicates. Groups were compared using
unpaired t-tests and One-Way Analysis of Variance (One-Way ANOVA) followed
by Tukey’s post-hoc test to correct multiple comparisons. Statistical analyses
were performed with GraphPad Prism software 4.01. Quantitative data for all
experimental analyses are presented as mean values ± S.E.M with unit value
assigned to control and the magnitude of differences among the samples being
expressed relative to the unit value of control.
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Results
27-OHC Increases Proliferation in ER+ Breast Cancer Cells
27-OHC has been reported to be a novel SERM and an agent that can promote
ER+ breast cancer growth (DuSell et al. 2008; Cruz, Torres, María E. Ramírez, et
al. 2010; Nelson et al. 2013; Wu et al. 2013). As cell proliferation is considered a
hallmark of tumor growth and cancer progression (Gao et al. 2005), we
measured proliferation with and without 27-OHC treatment in ER-positive MCF7
and ER-negative MDA MB 231 cell lines. Treatment of MCF7 with 0.1 or 1µM 27OHC increased cell proliferation by about 80% compared to treatment with
vehicle (Fig. 9a). Treatment with estradiol of MCF7 cells also increased
proliferation in a magnitude comparable to that of 27-OHC. On the other hand,
the ER-negative cells MDA MB 231 did not exhibit significant proliferation when
treated with 27-OHC (Fig. 9b). These result are in accordance with the recent
discovery that 27-OHC binds to ER and exacerbates ER-positive breast cancers
(Umetani and Shaul 2011; Wu et al. 2013).
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Figure. 9: 27-OHC induces proliferation in breast cancer cell lines. (a)
Proliferation assay in the MCF7 cells shows an increase in proliferation 48h after
treatment with 0.1 or 1μM of 27-OHC and 2nM Estradiol (E2) compared to
treatment with vehicle. (b) In contrast to MCF7 cells, the MDA MB 231 cells
exhibit no change in proliferation in the presence of 27-OHC either at 0.1 or 1μM
concentration for 48h. Data is expressed as Mean ± S.E.M. ***p<0.001 versus
vehicle
27-OHC Reduces Transcriptional Activity of p53
p53 is often mutated in breast cancers, thus implicating disruption of this gene in
breast cancer progression. Moreover, p53 is a promising target in breast cancers
(Sørlie et al. 2001; Walerych et al. 2012). MCF7 is one of the few breast cancer
cells which has wild type p53, most ER+ breast cancer cell lines have mutated
p53 (Okumura et al. 2002; Wasielewski et al. 2006). We used the MCF7 cell line
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which is a commonly used cell model for breast cancer therapeutics studies
(Comşa et al. 2015; Lee et al. 2015). Published work suggests that 27-OHC
stimulates cell proliferation in breast cancer cells but not in normal breast
epithelial cells (Cruz, Torres, María E. Ramírez, et al. 2010; Nelson et al. 2013;
Wu et al. 2013). Since MCF7 cells express wild type p53, it is vital to examine the
impact of 27-OHC on p53 activity (Okumura et al. 2002; Zheng et al. 2004;
Wasielewski et al. 2006; Lim et al. 2009). Subsequently, we transfected cells with
a luciferase reporter linked to a p53 receptor element and treated with 27-OHC.
Treatment of MCF7 cells with 0.1 or 1µM 27-OHC significantly decreased p53driven transcription by ~25% compared to incubation with vehicle (Fig. 10a).
Interestingly, treatment with estradiol did not induce changes in p53 activity
compared to vehicle (Fig. 10a). In the ER-negative MDA MB 231 cells, 27-OHC,
either at 0.1 or 1µM, exerted no detectable effect on p53 activity (Fig. 10b). To
test whether the 27-OHC effect on p53 mediated transcription was via ER, we
used fulvestrant, an ER inhibitor. We found that co-treatment with fulvestrant
attenuated the 27-OHC induced p53 inactivation (Fig. 10c). This result suggests
that inhibitory effect of 27-OHC on p53 is ER mediated.
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Figure 10: 27-OHC reduces p53 activation. (a) Luciferase reporter assay in
MCF7 cells showed lower p53 activity in the presence of 0.1μM 27-OHC, 1μM
27-OHC, or 2nM Estradiol (E2) for 24h. (b) No change in p53 activity was
detected with the luciferase reporter assay in the ER-negative MDA MB 231 cells
treated with 0.1μM or 1μM 27-OHC for 24h. (c) Luciferase reporter assay in
MCF7 cells demonstated that fulvestrant, an ER inhibitor, attenuates 27-OHC
induced p53 inactivity when treated with 1µM 27-OHC and/or 5µM of fulvestrant.
Data is expressed as Mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 versus
vehicle.##p<0.01 versus 27-OHC only. RLU=Relative Luciferase Units
27-OHC Regulates p53 and MDM2 Expression
Regulation of p53 degradation is important to maintain its activity. MDM2 plays a
critical role in regulating p53 levels by enhancing p53 degradation. MDM2
catalyzes p53 degradation by flagging it for destruction. In contrast, during DNA
damage MDM2 undergoes self-ubiquitination and downregulates its own
expression, which leads to the upregulation of the DNA damage response
through p53 (Moll and Petrenko 2003; Manfredi 2010). MDM2 is overexpressed
in human cancers where it causes the disruption of p53 signaling and potentially
other oncogenic pathways (Moll and Petrenko 2003; Manfredi 2010). We
determined the effect of 27-OHC on p53 and MDM2 expression levels using
western blot analyses. We found that treatment of cells with 27-OHC decreased
p53 expression levels by ~50% and increased MDM2 expression levels by ~28%
compared to vehicle (Fig. 11a-c). This result suggests that 27-OHC
downregulates p53 expression and upregulates MDM2 expression.
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Figure 11: 27-OHC reduces p53 and increases MDM2 levels. (a) Representative
western blot and densitometric analysis of MCF7 cells showing a substantial
decrease in p53 levels (b) and a significant increase in MDM2 levels (c) following
treatment with 1µM of 27-OHC for 24h. Data is expressed as Mean ± S.E.M.
*p<0.05 versus vehicle
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27-OHC Enhances p53 and MDM2 Dimerization
The relationship between p53 and MDM2 has been widely studied. MDM2 is
known to bind to p53 and shuttle it to the cytoplasm for degradation (AlarconVargas 2002; Moll and Petrenko 2003). To determine whether 27-OHC
enhances the interaction between MDM2 and p53, we performed a coimmunoprecipitation assay. We found that treatment with 27-OHC increased
MDM2 and p53 binding. When MDM2 was blotted against p53 immunoprecipitated lysate or when p53 was blotted against MDM2 immuno- precipitated
lysate, an increase in staining for the other protein was observed (Fig. 12a). We
also used double immunofluorescence staining to observe p53-MDM2 colocalization. Subsequently, we found that 27-OHC treatment, caused a significant
increase in overlap of labelled p53 and MDM2 at the nuclear envelope (Fig.
12b,c). This indicates that 27- OHC enhances the physical interaction between
p53 and MDM2.
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Figure 12: 27-OHC promotes p53-MDM2 interaction in MCF7 cells. (a)
Representative non-denatured western blots for p53 IP blotted against MDM2
and MDM2 IP blotted against p53 demonstrating an increase in p53-MDM2
binding in of MCF7 cells treated for 24h as follows: lane 1 Rabbit Serum
(negative control); lane 2: lysate only; lane 3, 4: vehicle only; lane 5,6: 1µM 27OHC. (b) Representative confocal microscopy images showing increased
intensity of MDM2 staining (green) and reduced intensity of p53 staining (red)
following treatment of MCF7 cells with1µM 27-OHC. Arrows indicate colocalization of p53 and MDM2 in MCF7 cells treated with 1µM 27-OHC for 24h.
Bar, 10µm. (c) Representative graph showing increased percent of overlap
between MDM2 and p53 in the confocal images. Data is expressed as Mean ±
S.E.M. *p<0.05 versus vehicle
27-OHC Increased Proliferation via MDM2 Mediated p53 Inactivity
To determine whether 27-OHC promotes cell proliferation via p53 inactivation;
we treated cells with the p53 activator, Tenovin-1 (Lain et al. 2008). We found
that Tenovin-1 significantly increased p53 transcriptional activity (Fig 13a) and
inhibited 27-OHC-induced proliferation (Fig. 13b). This suggests that p53
inactivation is necessary for 27-OHC induced cell proliferation. Given that 27OHC treatment increased MDM2 levels, enhanced MDM2-p53 binding and
decreased p53 levels (Fig. 11&12), we tested whether if 27-OHC-induced cell
proliferation was due to MDM2 dependent p53 degradation. We treated cells with
the MDM2-p53 interaction inhibitor, Nutlin-3 (Park et al. 2013). We found that
Nutlin-3 blocked 27-OHC-induced cell proliferation comparable to that of basal
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levels (Fig. 13c). This result suggests that MDM2-p53 binding is required for 27OHC induced cell proliferation. To investigate if MDM2 expression is specifically
necessary for 27-OHC induced cell proliferation, we knocked down MDM2
expression using siRNA. Inhibition of MDM2 blocked 27-OHC induced cell
proliferation (Fig. 13d,e). This data strongly suggests that 27-OHC requires
MDM2-mediated p53 degradation to induce cell proliferation.
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Figure 13: 27-OHC induces proliferation via MDM2-mediated p53 inactivation. (a)
Luciferase reporter assay demonstrates an increase in p53 activity in MCF7 in
the presence of 10μM Tenovin-1 for 48h. (b) Cell proliferation assay
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demonstrates that 27-OHC-induced proliferation is attenuated by Tenovin-1 in
MCF7 cells. Cells were treated vehicle, 1μM 27-OHC, 10μM Tenovin-1, or 1μM
27-OHC + 10μM Tenovin-1 for 48h. (c) In MCF7 cells, 1μM 27-OHC-induced
proliferation is also attenuated by the MDM2-p53 interaction inhibitor Nutlin-3.
Cells were treated with vehicle, 1μM 27-OHC, 5μM Nutlin-3, or 1μM 27-OHC +
5μM Nutlin-3 for 48h. (d) Representative blot demonstrates MDM2 knock down
efficiency in MCF7. (e) 1μM 27-OHC-induced proliferation is also attenuated by
MDM2 siRNA. Cells were incubated with respective treatments for 48h. Data is
expressed as Mean ± S.E.M. versus vehicle. Data is expressed as Mean ±
S.E.M. *p<0.05, **p<0.01, ***p<0.001 versus vehicle, and

###

p<0.001 versus 27-

OHC only. RLU=Relative Luciferase Units
Discussion
The goal of this study was to elucidate cellular mechanisms involved in
27-OHC-induced proliferation in breast cancer cells. Our results demonstrate that
27-OHC decrease p53 activity and protein levels, which results in increased cell
proliferation. Our study also shows that 27-OHC increases MDM2 levels and
enhances the interaction between p53 and MDM2. We further show that 27OHC-induced proliferation is dependent on MDM2-mediated p53 degradation.
Our results are the first showing that 27-OHC acting through ER, exacerbates
breast cancer cell proliferation via the p53-MDM2 axis.
P53 is a highly regulated protein in the cell and has a short half-life
(Giaccia and Kastan 1998). Loss of p53 function and/or perturbations in its
signaling pathways via mutations plays an important role in several cancers
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(Hanahan and Weinberg 2000; Sherr and McCormick 2002; SHERR 2004). p53
plays an important role in “guarding the genome” from genotoxic stress and
regulates apoptosis, cell cycle, senescence and metabolism. Lack of functional
p53 leads to abnormalities in cell cycle and apoptosis, which may lead to cancer
progression. Approximately, 23% of breast cancers exhibit a p53 mutation and
loss of p53 function via mutation remains one of the main molecular
characteristics of breast carcinomas, while more spontaneous cancers such as
ovarian, intestinal, and lung cancers have higher incidences of p53 mutations
(Walerych et al. 2012; Yu et al. 2014 Apr 23). In this report, we show that the
cholesterol oxidation metabolite 27-OHC dysregulates p53 expression and
function.
We report that 27-OHC, a SERM, inhibited wild type p53 activity, while
interestingly, estradiol, a standard and endogenous ligand for ER had no effect
on p53 activity. This demonstrates that 27-OHC may contribute to ER-positive
breast cancer progression via different mechanisms compared to known
estrogens. To verify that 27-OHC exerted it effects via ER, we treated cells with
fulvestrant, an ER inhibitor, concomitantly with 27-OHC and found that it blocked
the p53 transcriptional inactivation effects of 27-OHC. This demonstrates that
while 27-OHC and estradiol activate the same receptor (ER), the downstream
events appear to be distinct. Regulation of estrogen levels in humans has been
extensively studied and is a primary target for therapy using interventions such
as aromatase inhibitors and ovarian ablation (Gonzalez-Angulo et al. 2007).
Although hormone therapy is relatively effective, such therapy is challenged by
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endocrine resistance and recurrence of breast cancers. Hormone therapy is
designed to specifically reduce estrogen levels (Hasson et al. 2013; Jankowitz
and Davidson 2013). The recent discovery that 27-OHC also activates ER and
promotes ER-positive breast cancer progression, may explain why hormone
therapy may not be as effective as expected. Furthermore, a recent study by
Nelson and colleagues demonstrated that the gene expression profile in MCF7
breast cancer cells grown in the presence of 27-OHC was remarkably different
relative to estradiol-treated MCF7 cells, with 788 unique genes in the 27-OHC
profile that are different from the estradiol profile of 8141 genes (Nelson et al.
2013). In the above mentioned study, 27-OHC and estradiol regulated 1511
shared genes (Nelson et al. 2013). Understanding the role of 27-OHC in ERpositive breast cancer may reveal novel molecular mechanisms that play a role in
breast cancer progression, resistance and recurrence of breast cancers.
There is a positive correlation between cholesterol and 27-OHC levels in
humans. Patients with hypercholesterolemia have higher levels of 27-OHC and
thus may be at a greater risk for developing ER-positive breast cancer (Nelson et
al. 2013). 27-OHC is synthesized from cholesterol through hydroxylation by a
cytochrome P-450 enzyme, sterol 27 hydroxylase (CYP27A1), localized in the
inner mitochondrial membrane of the liver. 27-OHC is a substrate for bile acid
synthesis, and when bile acid levels are adequate, excess levels of 27-OHC are
catabolized by CYP7B1 (Fu et al. 2001; Ma et al. 2014 May 1). In support of
hypercholesterolemia as a risk factor for developing breast cancers, the use of
cholesterol lowering agents, such as HMG-CoA reductase inhibitors (statins),
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has been associated with better prognosis and breast cancer survival rates
(Ahern et al. 2011). Furthermore, Cruz et al showed that in ER-positive
mammary tumor cells, simvastatin blocked 27-OHC induced cell proliferation
(Cruz, Torres, María E. Ramírez, et al. 2010).
Our results add further insights into the potential molecular mechanisms
by which 27-OHC influences cancer cell progression. We show that 27-OHC
increases levels of the E3 ubiquitin ligase MDM2 and its interaction with p53.
MDM2 is known to regulate p53 activity by flagging it for ubiquitination and
proteasomal degradation (Alarcon-Vargas 2002). Since DNA damage is a potent
activator of p53, prior to DNA damage MDM2 binds to both p53 and ribosomal
protein RPL26 resulting in ubiquitination and proteasomal degradation. Upon
DNA damage, p53 and MDM2 undergo posttranslational modifications, inhibiting
their interaction and subsequently activating p53 activity (Moll and Petrenko
2003; Khoo et al. 2014). In the presence of 27-OHC, MDM2 and p53 interaction
is enhanced, resulting in p53 inactivation and degradation. It is suggested that
MDM2 by itself may be an oncogene (Momand 1998; Wang et al. 1999). MDM2
is overexpressed in various cancers including sarcoma, leukemia, breast
cancers, melanoma, and glioblastoma (Jones et al. 1998; Momand 1998).
We also demonstrate that 27-OHC-induced cell proliferation in the ERpositive breast cancer MCF7 cells is dependent on the inactivation of p53.
Treatment with Tenovin-1, a potent p53 activator, attenuated 27-OHC-induced
cell proliferation. This supports the notion that 27-OHC induced p53 inactivation
promotes breast cancer cell proliferation. Since p53 can undergo inactivation and
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degradation through multiple mechanisms (Moll and Petrenko 2003; Kruse and
Gu 2009; Tsvetkov et al. 2010), it was vital to test the role of MDM2 specifically in
27-OHC induced p53 inactivation that led to cell proliferation. To verify whether
p53 inactivation is MDM2-dependent, we treated cells with Nutlin-3, an MDM2p53 interaction inhibitor (Miyachi et al. 2009; Poyurovsky et al. 2010). We found
that Nutlin-3 prevents MDM2 mediated and 27-OHC-induced degradation of p53.
We also found that upon knocking down MDM2, 27-OHC induced cell
proliferation was attenuated, suggesting that inactivation of p53 is MDM2
dependent. This data indicates that 27-OHC exacerbates ER-positive breast
cancer progression by inactivating and degrading p53 via MDM2.
Although the prognostic value of p53 in ER-positive breast cancers is
controversial, we propose that in the presence of excess 27-OHC, p53 function is
compromised via MDM2, causing an exacerbation of ER-positive breast cancer
progression. Subsequently, activation of p53 has been considered to be an
important therapeutic target in tumorigenesis and cancer progression. A number
of small molecules have been developed to activate wild type p53 and reactivate
mutant p53. Interestingly, both DNA based and dendritic cell delivered p53
vaccines have been developed to activate and upregulate p53 (van der Burg et
al. 2001; Speetjens et al. 2009). In addition, gene therapy has been used against
breast carcinomas (Obermiller et al. 2000; Sasaki et al. 2001; Song and Boyce
2001; Rejeeth and Kannan 2014 May 4). Recently, Rejeeth et al. (2014) used
silica nanoparticle supplemented with transferrin to administer p53 to MCF-7 and
showed that such a treatment reduced cell growth by 60.7%.
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Figure 14: Proposed mechanism of action of 27-OHC in ER+ breast cancer. 27OHC activates ER, which upregulates MDM2 and mediates p53 inactivation and
degradation resulting in increased in cell proliferation. Thus, exacerbating ER+
breast cancer progression. Activation is denoted by arrows; inhibition is indicated
by bars
In summary, we demonstrate that 27-OHC exacerbates ER-positive MCF7
cancer cell proliferation by disrupting p53 activity. We propose that 27-OHC
activates ER, an effect that leads to activation of MDM2 and subsequent
inactivation of p53. Fulvestrant, an ER specific antagonist, blocks 27-OHC
activation of ER, resulting in disinhibition of Mdm2-mediated p53 transcriptional
activity. It has been shown that ER activation enhances MDM2 expression and
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that fulvestrant attenuates MDM2 upgregulation by inhibiting ER (Dolfi et al.
2014). Since ER upregulates MDM2, which in turn inactivates p53, we asked if
fulvestrant would inhibit MDM2-mediated p53 inactivation. Indeed, when we
measured p53 activity, we found that fulvestrant inhibited 27-OHC-induced
Mdm2-mediated p53 inactivation (Fig.10). Our data indicates that 27-OHC acting
through ER can disrupt the p53 response. We suggest that individuals with high
levels of 27-OHC may have an increased risk of developing ER-positive breast
cancers via loss of constitutive p53 activity. We also demonstrate that 27-OHC
enhances MDM2-p53 interaction resulting in loss of p53 expression and activity.
Such results strongly suggest an MDM2 involvement in the 27-OHC-induced p53
inactivity and subsequent cell proliferation (Fig. 14). Our findings provide a novel
molecular mechanism for 27-OHC that may contribute in the pathophysiology of
ER-positive breast cancers. Understanding the MDM2-p53 interplay in the
presence of 27-OHC may reveal innovative therapeutic avenues that can inhibit
ER-positive breast cancer progression.
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CHAPTER III
ROLE OF 27-HYDROXYCHOLESTEROL IN PROSTATIC HYPERPLASIA
27-hydroxycholesterol Stimulates Cell Proliferation and Resistance to
Docetaxel-induced Apoptosis in Prostate Epithelial Cells
Abstract
Although the causes of prostate cancer (PCa) and benign prostatic hyperplasia
(BPH) are not known, the role of oxidative stress, aging, and diet are suspected
to increase the incidence of prostate complications. The cholesterol oxidation
derivative (oxysterol) 27-hydroxycholesterol (27-OHC) is the most prevalent
cholesterol metabolite in the blood. As aging, oxidative stress, and
hypercholesterolemia are associated with increased risk of PCa and BPH, and
because 27-OHC levels also increased with age, hypercholesterolemia and
oxidative stress, determining the role of 27-OHC in the progression of PCa and
BPH is warranted. In this study, we determined the effect of 27-OHC in human
prostate epithelial cells RWPE-1. We found that 27-OHC stimulates proliferation
and increases androgen receptor (AR) transcriptional activity. 27-OHC also
increased PSA expression and enhanced AR binding to the androgen response
element compared to controls. Silencing AR expression with siRNA markedly
reduced the 27-OHC-induced proliferation. Furthermore, 27-OHC blocked
docetaxel-induced apoptosis. Altogether, our results suggest that 27-OHC may
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play an important role in PCa and BPH progression by promoting proliferation
and suppressing apoptosis.
Introduction
Prostate health is an area of growing concern. Over 14% of men will
develop prostate cancer (PCa) and greater than 70% of men will develop benign
prostatic hyperplasia (BPH) by the age of 70 (Guess et al. 1990; Delongchamps
et al. 2006). The etiologies of PCa and BPH are unknown but environmental
factors including diet are suggested to play a role in the progression of these
pathologies. Aging, genetic susceptibility, obesity, low physical activity,
androgens, and inflammatory conditions are all associated with both PCa and
BPH (Chokkalingam et al. 2003; Ørsted and Bojesen 2013).
Cholesterol involvement in PCa has been suspected for over a century
when it was found to accumulate in PCa cells (White 1909). More recent studies
demonstrated a positive correlation between high plasma cholesterol and highgrade PCa (Mondul et al. 2010). Moreover, some studies reported a reduction in
the risk of high-grade PCa (Breau et al. 2010; Papadopoulos et al. 2011) and
BPH (Lee et al. 2013) with the cholesterol-lowering statins. However, the efficacy
of lowering cholesterol levels currently is not proven and whether increased
cholesterol levels are causal factors of PCa and BPH is still unknown.
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Several lines of evidence suggest that cholesterol oxidation products, not
cholesterol per se, may increase the risk of PCa and BPH risk. 27-OHC is the
main oxysterol in the circulation, and its levels can be increased by aging,
oxidative stress, and hypercholesterolemia (Hirayama et al. 2009; Nelson et al.
2013), factors that are all suspected to increase the risk for PCa and BPH.
Evidence suggests that 27-OHC can be deleterious as it can act as a SERM
(DuSell et al. 2008; Umetani and Shaul 2011) and a liver X receptor (LXR) ligand
(Fu et al. 2001). Both ER and LXR are involved in steroid signaling pathways and
influence inflammation, cell proliferation, and many other metabolic processes.
However, the extent to which 27-OHC also regulates androgen receptors (AR)
which play a central role in the pathogenesis of BPH and PCa is yet to be
determined. In this study we determined the effects of 27-OHC on cell
proliferation and the role of AR in 27-OHC induced cell proliferation.
We found that 27-OHC increases cell proliferation and AR transcriptional
activity. We also demonstrate that 27-OHC enhances AR binding to the Prostate
Specific Antigen (PSA) promoter and increases PSA expression. To investigate
whether AR is required in 27-OHC-induced cell proliferation, we silenced AR
gene expression using siRNA and found that 27-OHC induced cell proliferation is
AR dependent. Additionally, to determine whether 27-OHC contributes to
apoptosis-resistance, we treated cells with 27-OHC and docetaxel and found that
27-OHC inhibits the pro apoptotic effects of docetaxel by visualizing nuclear
fragmentation using TUNEL assay. Overall, our data supports the notion that 27-
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OHC induces cell proliferation in an AR-dependent manner and that 27-OHC
exhibits anti-apoptotic activities in prostate cells.
Methods
Reagents
27-OHC was purchased from Santa Cruz Biotechnologies (Dallas, TX), docetaxel
and fulvestrant from Cayman Chemicals (Ann Arbor, MI), β-estradiol from SigmaAldrich (St. Louis, MO) and the reporter constructs encoding androgen receptor
response elements conjugated to the firefly luciferase gene from SA Biosciences
(Valencia, CA). All cell culture reagents, with the exception of fetal bovine serum
(FBS) (Atlanta Biologicals; Flowery Branch, GA) were from Invitrogen. Human
RWPE-1 cells were purchased from ATCC (Manassas, VA). Concentrations of
solvent in treatments was less than 0.1%.
Cell Culture
Non-tumorigenic human prostate epithelial RWPE-1 cells were maintained in
Keratinocyte serum free medium (Invitrogen; Carlsbad, CA) supplemented with
0.05mg/ml BPE and 5ng/ml EGF. Cells were supplemented with 100U/ml
penicillin, 100μg/ml streptomycin 0.25μg/ml amphotericin (Sigma; St.Louis, MO)
and cultured at 5% CO2 and 37˚C. Cells were treated with vehicle (ethanol in
media), 0.1 μM or 1μM of 27-OHC. Stock solutions of 27-OHC were prepared in
100% ethanol and stored at -80°C. 27-OHC stock solution was dissolved in
appropriate volumes of media to prepare the working solutions of 0.1 μM or 1μM.
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Our study was approved by the Institutional Biosafety Committee at the
University of North Dakota.
Cell Proliferation Assays
To determine the effects of 27-OHC on cell proliferation, we treated cells with 27OHC at concentrations that have been shown to promote breast cancer
progression (Cruz, Torres, María E. Ramírez, et al. 2010; Nelson et al. 2013; Wu
et al. 2013). Proliferation assays were conducted on black 96 well plates using
CyQUANT Direct Cell Proliferation Assay (Invitrogen; Carlsbad, CA) which
quantifies cell number using DNA content and membrane integrity. Cells seeded
at 5x103 cells/well were treated with vehicle, 0.1 μM or 1μM of 27-OHC and
incubated for 48 hours. Cells were then stained as per the manufacturer’s
protocol and read using Spectra MAX GEMINI EM (Molecular Devices;
Sunnyvale, CA).
Metabolic Activity Assay
Cell metabolic activity was quantified by measurement of the reduction of
MTS to formazan product using CellTiter 96® AQueous One Solution Cell
Proliferation Assay (Promega; Madison, WI) according to the manufacturer’s
protocol. The assay of the formation of formazan was performed by measuring
absorbance change using a microplate reader (Spectromax plus; Molecular
Devices; Sunnyvale, CA) 48 h after treatments.
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Dual Luciferase Assays
Dual luciferase assays were conducted on white 96 well plates using the Dual
Luciferase Reporter Assay System (Promega; Madison, WI). Cells were
incubated for 18 hours with transfection ready AR response element conjugated
with firefly luciferase construct and constitutively expressing Renilla Luciferase
construct using Lipofectamine 2000 (Invitrogen; Carlsbad, CA) as per the
manufacturer’s protocol. Following transfection cells were treated with 0
(vehicle), 0.1 or 1μM 27-OHC for 24 hours. After 24 hours of treatment, cells
were lysed and measured in Relative Luciferase Units (RLU) as per the
manufacturer’s protocol. Firefly luciferase readings were normalized against
constitutive Renilla luciferase readings.
Chromatin Immunoprecipitation (ChIP) Analysis
ChIP analysis was performed to evaluate the extent of AR binding to the DNA
elements in the androgen receptor elements (ARE) regions respectively using
SimpleChIP™ Enzymatic Chromatin IP kit (Cell Signaling; Beverly, MA). Briefly,
cells from each treatment group (1×10 7 cells) were washed with PBS,
trypsinized, and centrifuged at 5000 g. The pellet containing the cells was further
washed with PBS and cross-linked using 37% formaldehyde for 15 min followed
by the addition of glycine solution to cease the cross-linking reaction. The cells
were washed with 4x volumes of 1x PBS and centrifuged at ~300g for 5 min. The
pellet was re-suspended and incubated for 10 min in 5 ml of cell lysis buffer
containing DTT and protease and phosphatase inhibitors. The cross-linked
chromatin from each sample was apportioned into three equal parts. One third of
47

the cross-linked chromatin was set aside as “input”. One third of the cross-linked
chromatin from each sample was incubated with 5 µg of AR rabbit antibody
(Active Motif), while the remaining one third of the cross-linked chromatin from
each sample was incubated with 5 µg of normal Rabbit IgG to serve as negative
control. The cross-linked chromatin samples were incubated overnight at 4°C
with their respective antibodies. The DNA-protein complexes were collected
using Protein G agarose beads. The samples were incubated with 2 µL of
Proteinase K for 2 hours at 65°C. The crude DNA extract was eluted and then
washed several times with wash buffer containing ethanol followed by purification
with the DNA spin columns. The pure DNA was eluted out of the DNA spin
columns using DNA elution buffer. The relative abundance of the AR antibody
precipitated chromatin containing the AR binding site in the ARE region was
determined by qPCR using an SYBR Green Mastermix kit following the
manufacturer’s instructions (Invitrogen; Carlsbad, CA). ARE sequence on the
PSA promoter F: 5′-TCTGCCTTTGTCCCCTAGAT-3′ and R: 5′AACCTTCATTCCCCAGGACT-3′ (Horie-Inoue et al. 2004). The amplification
was performed using Step NE plus PCR Detection System (Invitrogen; Carlsbad,
CA). The fold enrichment was calculated using the ΔΔCt method which
normalizes ChIP Ct values of each sample to the % input and background.
Western Blot Analysis
Treated cells were washed with PBS, trypsinized, and centrifuged at 5000 g. The
pellet was washed with PBS and homogenized in M-PER tissue protein
extraction reagent (Thermo Scientific; Waltham, MA) supplemented with
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protease and phosphatase inhibitors. Denatured proteins (5 µg) were separated
in 10% or 12.5% SDS-PAGE gels, transferred to a PVDF membrane (Millipore)
and incubated with antibodies to PSA (1:1000, Santa Cruz; Dallas,TX), or AR
(1:1000, Santa Cruz; Dallas, TX). β-actin was used as a gel loading control. The
blots were developed with enhanced chemiluminescence (ECL Clarity kit, BioRad). Bands were visualized on a polyvinylidene difluoride membrane and
analyzed by LabWorks 4.5 software on a UVP Bioimaging System. Quantification
of results was performed by densitometry and the results analyzed as total
integrated densitometric values (arbitrary units).
Small interfering RNA
The cells were transfected with AR siRNA using Lipofectamine 2000 (Invitrogen;
Carlsbad, CA) and incubated for 24 hours, followed by their respective
treatments. siRNA to AR sense and antisense strands were: 5’CGGGAAGUUUAGAGAGCUATT-3’,: 5’UAGCUCUCUAAACUUCCCGTG-3’
(Hs_AR_5, SA Biosciences; Valencia, CA).
TUNEL Assay
The TUNEL assay was performed using DeadEnd Fluorometric TUNEL assay
(Promega; Valencia, CA) for detection of apoptosis. The TUNEL staining was
performed according to manufacturer's instructions. Cells were permeabilized
with Triton-X, washed with PBS, and incubated with terminal deoxynucleotidyl
transferase, fluorescein-12-dUTP. The fluorescein-12-dUTP labeled DNA was
then visualized directly by fluorescence microscopy. DAPI was used as counter
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stain for staining the nucleus. Slides were visualized using DMI 6000 (Leica
Microsystems; Buffalo Grove, IL).
Statistical analysis
The significance of differences were assessed by unpaired t-test and One Way
Analysis of Variance (One Way ANOVA) followed by Tukey’s post-hoc test.
Statistical analysis was performed with GraphPad Prism software 4.01.
Quantitative data for experimental analysis are presented as mean values ±
S.E.M with unit value assigned to control and the magnitude of differences
among the samples being expressed relative to the unit value of control.
Results
27-OHC increases cell proliferation
We found that 27-OHC increases proliferation by ~60% at 0.1 µM and
~40% at 1.0 µM (Fig 15a). To confirm our results, we performed MTS assay to
assess the mitochondrial activity of cells. We found that 27-OHC (0.1 and 1 µM)
also increased the metabolic activity of the cells (Fig 15b). This data suggests
that 27-OHC induces cell proliferation in prostate epithelial cells.
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Figure 15: 27-OHC induces proliferation in prostate cells. Cell proliferation assay
in RWPE-1 (a) cells demonstrates a significant increase in proliferation in the
presence of 27-OHC (0.1 and 1μM). MTS assay shows a significant increase in
cell metabolic activity in the presence of 27-OHC in RWPE-1 (b). Readings were
recorded 48 hours after treatment with 27-OHC. Data is expressed as Mean ±
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S.E.M. ***p<0.001 and **p<0.01 versus controls, ###p<0.001 and ##p<0.01
versus 0.1 μM 27-OHC treatment.
27-OHC increases AR transcriptional activity
We treated cells with 27-OHC and measured the transcriptional activity of AR
using an ARE tagged luciferase reporter. We found that 27-OHC treatment
significantly increased AR transcriptional activity (Fig. 16).

Figure 16: 27-OHC increases AR transcriptional activity. Luciferase reporter
assay shows an increase in AR transcriptional activity in the presence of 27-OHC
(0.1 and 1μM) in RWPE-1 cells. Readings were recorded 24 hours after
treatment. Data is expressed as Mean ± S.E.M. **p<0.01 versus controls.
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27-OHC increases PSA expression and AR binding to the PSA
promoter
Using western blot analyses, we showed elevated levels of PSA in 27OHC treated cells. PSA levels significantly increased with 0.1µM and 1.0µM of
27-OHC (Fig 17 a,b). To determine if the elevated levels of PSA were due to the
increase in AR transcriptional activity, we performed a ChIP assay to analyze AR
binding to the androgen receptor element (ARE) on the PSA promoter. We found
an increase in AR binding to the ARE of the PSA promoter by ~17 fold when
treated with 0.1µM of 27-OHC and ~11 fold when treated with 1µM of 27-OHC
(Fig. 17c). This data suggests that 27-OHC enhances AR mediated PSA
expression.

53

Figure 17: 27-OHC increases PSA protein levels via AR. Representative western
blot (a) and densitometric analysis (b) showing a significant increase in PSA
protein levels in RWPE-1 cells treated with 27-OHC (0.1 and 1μM) for 48 h. ChIP
analysis of AR binding to the ARE on the PSA promoter shows an increase in AR
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binding in the presence of 27-OHC that is higher with 0.1 than 1.0 μM
concentrations (c). Data is expressed as Mean ± S.E.M. ***p<0.001 versus
controls, ##p<0.01, and #p<0.05 versus 1µM 27-OHC treatment.
27-OHC-induced cell proliferation is dependent on AR
We found that siRNA to AR reduced the protein levels of AR in untreated cells
(Fig. 18a) and diminished cell proliferation in 27-OHC-treated cells (Fig. 18b).
This result suggests that 27-OHC-induced cell proliferation involves AR. As 27OHC does not directly bind to AR and is an ER modulator (Nelson et al. 2011;
Umetani and Shaul 2011; Wu et al. 2013), it was important to determine the role
of ER in prostate cell proliferation. We found that fulvestrant, an ER inhibitor,
when concomitantly treated with 27-OHC, attenuated 27-OHC induced cell
proliferation (Fig 18c). This result suggests that ER may function in concert with
AR to induce 27-OHC induced cell proliferation.
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Figure 18: 27-OHC-induced cell proliferation is AR dependent. Western blot
analysis (a) shows the efficiency of siRNA to AR with protein levels markedly
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lower in RWPE-1cells treated with siRNA to AR than with scrambled siRNA. Cell
proliferation assay (b) demonstrates that 27-OHC (0.1µM and 1.0 µM) increases
cell proliferation and co-treatment with siRNA to AR markedly reduces
proliferation. The assay was performed following a 24 hour incubation of RWPE1cells with the siRNAs on a 96 well plate with their respective treatments. Cell
proliferation assay (c) demonstrates that 27-OHC induced cell proliferation is
attenuated when treated with 10µM fulvestrant. Readings were recorded 48
hours after the treatments. Data is expressed as Mean ± S.E.M. ***p<0.001
versus vehicle only, ##p<0.01 versus 0.1µM 27-OHC only, ###p<0.001 versus 0.1
µM or 1µM 27-OHC only treatment.
27-OHC suppressed docetaxel-induced apoptosis
Docetaxel is an apoptosis-inducing agent (Mhaidat et al. 2007) and the current
chemotherapeutic drug of choice for advanced PCa (Petrylak 2000; Petrylak
2006; Hwang 2012; Kellokumpu-Lehtinen et al. 2013). To determine whether 27OHC contributes to chemoresistance, we treated RWPE-1 cells with 27-OHC and
docetaxel and monitored the number of apoptotic cells by TUNEL assay. We
found that docetaxel induced apoptosis and 27-OHC (0.1 or 1.0 µM) markedly
reduced docetaxel-induced apoptosis (Fig. 19). When an apoptotic signal is
induced, caspase 3 (pro-enzyme) is activated by cleavage to execute apoptosis
(Porter and Jänicke 1999; McIlwain et al. 2013). We found that docetaxel
increased levels of both the pro and active caspase-3 (p17). Co-treatment with
27-OHC opposed the docetaxel-induced increase in pro caspase (Fig. 20 a,b)
and active caspase-3 levels (Fig. 20 a,c).
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Figure 19: 27-OHC opposes docetaxel-induced apoptosis. Confocal images
panels (a) and quantitation (b) for TUNEL assay in RWPE-1 cells treated with 27OHC and/or docetaxel for 24 h. Docetaxel (0.1µM) induced a marked increase in
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the apoptotic cells (Green) and treatment with 27-OHC at both 0.1 and 1.0 µM
diminished apoptosis induced by docetaxel. Bar: 100µM.
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Figure 20. 27-OHC reduces docetaxel-induced caspase-3 cleavage.
Representative western blot (a) and densitometric analysis (b) showing a
significant increase in pro-caspase protein levels in RWPE-1 cells when treated
with 0.1µM docetaxel and concomitant treatment with 27-OHC markedly reduced
pro-caspase protein levels. Representative western blot (a) and densitometric
analysis (c) showing a significant increase in cleaved caspase (active, p17)
protein levels in RWPE-1 cells when treated with 0.1µM docetaxel. Co-treatment
with 27-OHC markedly reduced cleaved caspase protein levels. Data is
expressed as Mean ± S.E.M. *p<0.05 versus controls, #p<0.05 versus docetaxel
only treatment, +p<0.05 and ++p<0.01 versus controls.
Discussion
This study was designed to determine the effects of 27-OHC on prostate
cell proliferation and apoptosis. We also determined the involvement of AR in cell
proliferation induced by 27-OHC. We demonstrate that 27-OHC increases
proliferation and activates AR transcriptional activity in the normal prostate cells
RWPE-1. We further demonstrate that 27-OHC-induced cell proliferation is AR
dependent. Additionally, we show that 27-OHC opposes apoptotic cell death
induced by docetaxel. Our data suggests that 27-OHC increases proliferation in
normal epithelial prostate cells in an AR dependent manner.
27-OHC, the most abundant cholesterol metabolite in the circulatory
system, is synthesized by the cytochrome P-450 enzyme, sterol 27 hydroxylase
(CYP27A1), in the inner mitochondrial membrane of the liver and is metabolized
by CYP7B1 enzyme (Fu et al. 2001; Ma et al. 2014 May 1). The main source of
61

27-OHC levels in the human body emanates from oxidation of cholesterol. As
cholesterol levels increase following intake of diets rich in cholesterol or
overproduction of endogenous cholesterol, production of 27-OHC increases.
Patients with hypercholesterolemia were reported to have high levels of 27-OHC
in their blood (Hirayama et al. 2009; Nelson et al. 2011; Nelson et al. 2013).
Additionally, 27-OHC levels in the plasma have been shown to increase with age
in males but not in females (Burkard et al. 2007a). Also, males are known to
have higher basal levels of 27-OHC in plasma than females (Dzeletovic et al.
1995; Burkard et al. 2007a). 27-OHC is also known to activate or inhibit nuclear
receptors depending on the target tissue. For instance, 27-OHC inhibits ER
signaling in the vasculature (Umetani et al. 2007b) and bone (DuSell et al. 2010),
however it activates ER signaling in breast (Cruz, Torres, María E. Ramírez, et
al. 2010; Nelson et al. 2013; Wu et al. 2013).
To the best of our knowledge, there has been no established link between
27-OHC, PCa and BPH. In this study, we report an increase in cell proliferation in
prostate cells in the presence of 27-OHC at concentrations below (0.1 µM) or
above (1.0 µM) the physiological concentrations (Brown and Jessup 1999;
Marwarha and Ghribi 2015). Total 27-OHC (esterified + non-esterified) is found in
the human blood plasma ranging from 0.2 to 0.6 µM in a healthy individual
(Hirayama et al. 2009; Schüle et al. 2010). Also, It has been shown that the
levels of non-esterified 27-OHC, which is the most biologically active form of 27OHC (Meaney et al. 2000; Meaney et al. 2001), is reported to be less than 20%
of total 27-OHC in the human body (Burkard et al. 2007a; Ramirez et al. 2008;
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Bandaru and Haughey 2014). In disease conditions, such as cancer and
neurodegenerative diseases, macrophages migrate to affected areas and
release excess 27-OHC in the surrounding tissue (Cruz et al. 2012; Nelson et al.
2013; Bandaru and Haughey 2014). We also found that fulvestrant, an ER
inhibitor, attenuated 27-OHC induced cell proliferation to the same levels.
Overall, our data suggests that 27-OHC may play an important role in prostate
cell proliferation, which may result in the progression of BPH and/or PCa.
Androgen receptor (AR) plays an important role in prostate growth and
development. There is a positive relationship between AR transcriptional activity
and PCa progression (Heinlein and Chang 2004; Lonergan and Tindall 2011).
Over 80% of PCa patients respond to anti-androgens or androgen deprivation
therapy that targets and inhibits the AR activity (Heinlein and Chang 2004; Y.
Chen et al. 2009). Additionally, androgens are also involved in BPH
pathogenesis via AR (Lu et al. 2012; Izumi et al. 2013). However, the effects of
cholesterol metabolites including the oxysterol 27-OHC on the AR signaling
pathway remain to be determined.
The AR signaling pathway plays a critical role in the development and
progression of PCa (Heinlein and Chang 2004; Lonergan and Tindall 2011; Izumi
et al. 2013). AR signaling is chiefly targeted in the context of PCa using androgen
ablation therapies (Heinlein and Chang 2004; Lonergan and Tindall 2011). As we
found that AR transcriptional activity was increased with 27-OHC treatment, we
determined the expression levels of prostate specific antigen (PSA), a wellknown downstream target of AR, increased in these cells (Saxena et al. 2012).
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PSA is a serine protease, which is produced by prostate epithelial cells and PCa
cells. It is used as a serum biomarker to monitor PCa progression in patients
(Kim and Coetzee 2004). Subsequently, we found that levels of PSA were
increased. Also, using a ChIP assay, we demonstrate that binding of AR to the
PSA promoter is increased in the presence of 27-OHC. We also show that 27OHC-induced proliferation is AR-dependent. When AR gene expression was
silenced, 27-OHC was unable to increase cell proliferation. As there was no
additive effect in proliferation when cells were treated simultaneously with 27OHC and E2 and because the ER selective inhibitor (Fulvestrant) prevented the
27-OHC-induced cell proliferation in RWPE-1 cells, we suggest the existence of
an ER-AR crosstalk in the presence of 27-OHC since we show that the AR
knockdown also reduces 27-OHC-induced proliferation.
Since 27-OHC levels increase with age (Burkard et al. 2007a), and 27OHC induce AR transcriptional activity, 27-OHC may play a role in castrateresistant prostate cancer. However, further studies are needed to evaluate the
role of 27-OHC in castrate-resistant PCa.
Apoptosis is an important process that keeps the number of cells dividing
under tight control (Hipfner and Cohen 2004). To assess the role of 27-OHC in
regulating apoptosis we utilized a pro-apoptotic drug, docetaxel (Mhaidat et al.
2007), a current chemotherapeutic drug of choice for advanced PCa (Petrylak
2006; Kellokumpu-Lehtinen et al. 2013).To further understand whether 27-OHC
plays a potential role in chemotherapeutic resistance, we treated cells with
docetaxel and 27-OHC. We found that 27-OHC attenuated the pro-apoptotic
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effects of docetaxel. While docetaxel is clinically used to battle metastatic PCa
(McKeage and Keam 2005), it is also pro-apoptotic in non-tumorigenic RWPE-1
cells (Karanika et al. 2015). To better understand the role of 27-OHC in PCa
further studies are needed, particularly metastatic PCa models. Our results
warrant further investigation to understand the anti-apoptotic role of 27-OHC in
chemotherapeutic resistance to PCa and BPH.
In summary, we demonstrate that 27-OHC induces an increase in
proliferation in normal prostatic epithelial cells in an AR dependent manner. We
also report for the first time, the docetaxel-resistant role of 27-OHC in epithelial
cells. Our study provides a novel insight into the molecular mechanisms of 27OHC and its role in modulating AR signaling pathway that is tightly linked to cell
proliferation which is associated with PCa and BPH. Further studies are
warranted to delineate the 27-OHC activated AR signaling pathway which may
lead to unraveling novel therapeutic avenues for PCa and BPH.
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CHAPTER IV
ROLE OF 27-HYDROXYCHOLESTEROL IN PROSTATE CANCER
The cholesterol metabolite, 27-hydroxycholesterol stimulates cell
proliferation via ERβ in prostate cancer cells
Abstract
For every six men, one will be diagnosed with prostate cancer (PCa) in
their lifetime. Estrogen receptors (ERs) are known to play a role in prostate
carcinogenesis. However, it is unclear whether the estrogenic effects are
mediated by estrogen receptor α (ERα) or estrogen receptor β (ERβ). Although it
is speculated that ERα is associated with harmful effects on PCa, the role of ERβ
in PCa is still ill-defined. The cholesterol oxidized metabolite 27hydroxycholesterol (27-OHC) has been found to bind to ERs and act as a
selective ER modulator (SERM). Increased 27-OHC levels are found in
individuals with hypercholesterolemia, a condition that is suggested to be a risk
factor for PCa. In the present study, we determined the extent to which 27-OHC
causes deleterious effects in non-tumorigenic RWPE-1 cells, the low tumorigenic
LNCaP cells, and highly tumorigenic PC3 prostate cancer cells. We found that
incubation of LNCaP and PC3 cells with 27-OHC significantly increased cell
proliferation. We also demonstrate that the ER inhibitor fulvestrant significantly
reduced 27-OH-induced cell proliferation, indicating the involvement of ERs in
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cell proliferation. Interestingly, ERβ levels, and to a lesser extent ERα, were
significantly increased following incubation of PCa cells with 27-OHC.
Furthermore, 27-OHC induced cell proliferation is attenuated in the presence of
the ERβ specific inhibitor, PHTPP. Altogether, our results show for the first time
that 27-OHC, through ER activation, triggers deleterious effect in prostate cancer
cell lines. We propose that dysregulated levels of 27-OHC may trigger or
exacerbate prostate cancer via acting on ERβ.
Introduction
Prostate cancer (PCa) is the second leading cause of death among men
in the United States (Ferlay et al. 2010). The causes for PCa appear to be
multifactorial, however it is well established that the incidence of PCa increases
with age (Ferlay et al. 2010; Zhou et al. 2016). Several risk factors are
associated with PCa including aging (Zhou et al. 2016), obesity (Gann 2002),
hormonal imbalance (Gann 2002), oxidative stress (Gann 2002; Bostwick et al.
2004) and hypercholesterolemia (Magura et al. 2008; Moon et al. 2015).
ER signaling has been implicated in PCa; the isoform ERβ, and to a lesser
extent ERα, is expressed in prostate epithelial and stromal cells (Bonkhoff et al.
1999; Hartman et al. 2012). ERα is considered pro-proliferative (Chakravarty et
al. 2014) and ERβ anti-proliferative in the context of PCa (Weihua et al. 2002;
Imamov et al. 2004; McPherson et al. 2008). However ERβ agonists have not
shown clinical promise to combat PCa (Roehrborn et al. 2015) and there is a gap
in knowledge elucidating the role of ERβ in PCa.
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27-hydroxycholesterol (27-OHC) is the most abundant cholesterol
metabolite in the periphery (Fu et al. 2001; Ma et al. 2014 May 1). Also, 27-OHC
in plasma increases with age, especially in men (Burkard et al. 2007a). Men also
have higher basal levels of 27-OHC in the plasma than women (Burkard et al.
2007a). Moreover, while patients with hypercholesterolemia are at risk for
developing PCa (Magura et al. 2008), they also have increased 27-OHC levels in
the blood (Hirayama et al. 2009; Nelson et al. 2011; Nelson et al. 2013).
Understanding the role of 27-OHC in the context of PCa is critical and may reveal
the underlying mechanisms responsible for PCa tumor initiation and progression.
27-OHC is a selective estrogen receptor modulator (SERM) that has been
identified to bind to ER and modulate its activity (Umetani et al. 2007a; Umetani
and Shaul 2011). 27-OHC levels are higher among those with
hypercholesterolemia (Hirayama et al. 2009; Nelson et al. 2011; Nelson et al.
2013) and older men (Burkard et al. 2007b), both of which are at high risk of
developing PCa. Also, 27-OHC-induced ER activation has been shown to
promote ER+ breast cancer growth and progression (Cruz, Torres, María
Eugenia Ramírez, et al. 2010; Nelson et al. 2013; Wu et al. 2013; Raza et al.
2015). Given that 27-OHC, at high levels, is associated with risk factors for PCa
(i.e., hypercholesterolemia and aging) and that 27-OHC modulates ER signaling,
a pathway that plays a role in PCa development and progression, it is essential
to study the role of 27-OHC in the context of PCa. Further understanding of the
role of 27-OHC in PCa may innovate alternative therapeutic avenues to those
that are currently on the market.
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We have previously shown that 27-OHC stimulates cell proliferation and
inhibits docetaxel induced apoptosis in non-tumorigenic prostate epithelial cells
(Raza et al. 2016). In this study, we determined a role for 27-OHC in activation of
ERs, leading to deleterious effects in PCa cells.
Methods
Reagents
27-OHC was purchased from Santa Cruz Biotechnologies (Dallas, TX),
docetaxel, 4-[2-Phenyl-5,7-bis(trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3yl]phenol (PHTPP) and Fulvestrant from Cayman Chemicals (Ann Arbor, MI) and
β-estradiol from Sigma-Aldrich (St. Louis, MO). All cell culture reagents, with the
exception of fetal bovine serum (FBS) (Atlanta Biologicals; Flowery Branch, GA)
were from Invitrogen (Carlsbad, CA). Human RWPE-1, LNCaP and PC3 cells
were purchased from ATCC (Manassas, VA).
Cell Culture
Non-tumorigenic human prostate epithelial RWPE-1 cells were maintained in
Keratinocyte serum free medium (Invitrogen; Carlsbad, CA) supplemented with
0.05mg/ml BPE and 5ng/ml EGF. Metastatic LNCaP cells were maintained in
RPMI 1640 medium and highly metastatic PC3 cells were maintained in F-12K
medium. LNCaP and PC3 cells were supplemented with 10% FBS. All cells were
supplemented with 100U/ml penicillin, 100μg/ml streptomycin 0.25μg/ml
amphotericin (Sigma; St. Louis, MO) and cultured at 5% CO 2 and 37˚C. Stock
solutions of 27-OHC were prepared in 100% ethanol and stored at -80°C. 2769

OHC stock solution was dissolved in appropriate volumes of media to prepare
the working solutions of 1μM, a concentration that we showed to cause
proliferation in prostate epithelial cells (Raza et al. 2016). Stock solutions of βestradiol were dissolved in 100% ethanol and stored at -80°C. Stock solutions
were diluted to prepare working solutions of 2nM. Stock solutions of PHTPP and
fulvestrant were also dissolved in 100% ethanol, stored at -20°C, and diluted
prior to treatment to prepare working solutions of 10μM. Concentrations of
solvent in treatments were less than 0.1%. Our study was approved by the
Institutional Biosafety Committee at the University of North Dakota.
Cell Proliferation Assay
Proliferation assays were conducted on black 96 well plates using CyQUANT
Direct Cell Proliferation Assay (Invitrogen; Carlsbad, CA), which quantifies cell
number using DNA content and membrane integrity. Cells seeded at 50-60%
confluence were treated and incubated for 48 hours. Cells were then stained as
per the manufacturer’s protocol and read using Spectra MAX GEMINI EM
(Molecular Devices; Sunnyvale, CA).
Metabolic Activity Assay (MTS assay)
Cell metabolic activity was quantified by measurement of the reduction of MTS to
formazan product using CellTiter 96® AQueous One Solution Cell Proliferation
Assay (Promega; Madison, WI) according to the manufacturer’s protocol. The
assay of the formation of formazan was performed by measuring absorbance
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change using a microplate reader (Molecular Devices; Sunnyvale, CA) 48 h after
treatments.
Western Blot Analysis
Treated cells were washed with PBS, trypsinized, and centrifuged at 5000 g. The
pellets were washed with PBS and homogenized in M-PER tissue protein
extraction reagent (Thermo Scientific; Waltham, MA) supplemented with
protease and phosphatase inhibitors. Denatured proteins (5 µg) were separated
in 10% SDS-PAGE gels, transferred to a PVDF membrane (Millipore; Billerica,
MA) and incubated with antibodies to ERα (1:1000, Santa Cruz; Dallas,TX) and
ERβ (1:1000, Millipore, Billerica, MA). β-actin was used as a gel loading control.
The blots were developed with enhanced chemiluminescence (ECL Clarity kit,
Bio-Rad). Bands were visualized on a polyvinylidene difluoride membrane and
analyzed by LabWorks 4.5 software on a UVP Bioimaging System. Quantification
of results was performed by densitometry and the results analyzed as total
integrated densitometric values (arbitrary units).
Invasion assay
Invasion Assays were conducted using QCM 96-well Cell Invasion Assay kit
(Millipore; Billerica, MA). The various treatments were added to the wells of the
feeder tray and at least 1x104 cells/well re-suspended in serum free medium
were added to the invasion chambers. Cells were incubated with treatments for
24 hours then stained as per manufacturer’s protocol and transferred to a black
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96 well plate to read fluorescence using Spectra MAX GEMINI EM (Molecular
Devices; Sunnyvale, CA).
Real-time Polymerase Chain Reaction (RT-PCR)
After treatments, cells were lysed according to QuickGene Mini80 protocol and
kit (Autogen). RNA sample were quantitated by spectrophotometry and
subsequently, 1µg total RNA was used as template to synthesize cDNA with the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems; Foster City,
CA). We selected genes involved in pathways related to 27-OHC, including
cholesterol metabolism (Björkhem 2013), liver X receptor (LXR) (Lehmann et al.
1997) and sonic hedgehog (Shh) (Javitt 2008) signaling. We also selected genes
involved in metastasis (Gorlov et al. 2010; Wang et al. 2013; Broustas and
Lieberman 2014), oxysterol binding (Vesa M. Olkkonen et al. 2012) and tumor
suppression(Bereczki et al. 2008). The screened genes are included in Table I.
Primers for all assays were designed using Primer Express 3.0 (Applied
Biosystems; Foster City, CA). Melting curve analysis was performed to ensure
single-product amplification for all primer pairs. Real time PCR was performed on
the ABI 7900HT Fast Real Time PCR System (Applied Biosystems; Foster City,
CA) using the panel of genes of interest. Data analysis was performed using
Sequence Detection System software from Applied Biosystems, version 2.4. The
experimental Ct (cycle threshold) was calibrated against the endogenous control
products alpha-ACTIN (ACTN1) and Beta-2-Microglobulin (B2M). Samples were
analyzed for relative gene expression by the DDCt method (Pfaffl 2001).
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Table 1: Selected Genes analyzed with their corresponding pathways
Cholesterol Metabolism

Nuclear receptor signaling

Shh signaling

CYP27A1

CYP7B1

HMGCR

ABCA1

EZH2

FOXA1

GLI1

GLI2

GLI3

NFKB1

SRD5A2

SREBF1

NR1H2

NR1H3

RXRA

PTCH1

PTCH2

SHH

RXRB

SIRT1

TFF1

SMO

TMPRSS2

Metastasis

Oxysterol Binding

CBX1

CBX5

CTGF

FN1

IGF-1

IGFBP3

MTA1

MTA3

SNAI1

SNAI2

SPARC

VEGFA

INSIG2

OSBP

Tumor Suppression
MDM2
TP53
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TAF3

TNF

Table 2: Primers used in determining mRNA expression of significantly regulated
genes
Gene
CBX1-f

Sequence
TGAGCAGCGTCACCCTTTACAC

CBX1-r

CCACTTTGCCCTTTACCACTCG

CBX5-f

TGGCACAATCTTGGCTTACTGT

CBX5-r

ATGGTGGCACACACCTGTAGTC

CTGF-f

AGGATGTGCATTCTCCAGCCATC

CTGF-r

TGTCAGAGCTGAGTCTGCTGTTC

CYP27A1-f

CAGCTGCGCTTCTTCTTTCAGC

CYP27A1-r

TGGCCTTGTAAAGCACCTGTAAC

FOXA1-f

TCCTCAGGAATTGCCCTCAAGAAC

FOXA1-r

ATGACATGACCATGGCACTCTGC

GLI2-f

TGTCTGAGTGACACCAACCAGAAC

GLI2-r

TGTGAATGGCGACAGGGTTGAC

GLI3-f

CCTCCAGCACCACTTCTAATGAGG

GLI3-r

TCTGTGGCTGCATAGTGATTGCG

IGFBP3-f

TCCAAGCGGGAGACAGAATATGG

IGFBP3-r

AGGAACTTCAGGTGATTCAGTGTG

INSIG2-f

CATGCCAGTGCTAAAGTGGATTTC

INSIG2-r

TGGATAGTGCAGCCAGTGTGAG

MDM2-f

TCCTCTCAAGCTCCGTGTTTG

MDM2-r

TCATGATGTGGTCAGGGTAGATG

MTA3-f

GCAGCAGAAGCTGAGAGTAAACTG

MTA3-r

TGGTTGGGATTTGGTTTGCTGTAG

NR1H2-f

GCATCCACTATCGAGATCATGCTG

NR1H2-r

GAAGGTGATACACTCTGTCTCGTG

OSBP-f

CTATGAAAGCCACAGAGGATGGC

OSBP-r

GTCCTTCTTCCGCTCAAACCAC

PTCH1-f

TCACCGTTCACGTTGCTTTGGC

PTCH1-r

AAACATGTGCTCCAGGGCAAGC

Gene
RXRB-f
RXRB-r
SIRT1-f
SIRT1-r
SPARC-f
SPARC-r
SRD5A2-f
SRD5A2-r
SREBF1-f
SREBF1-r
TAF3-f
TAF3-r
TFF1-f
TFF1-r
TMPRSS2f
TMPRSS2r
TNF-f
TNF-r
TP53-f
TP53-r
VEGFA-f
VEGFA-r
ACTINalph
a-f
ACTINalph
a-r
B2M-f
B2M-r
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Sequence
TGCTGTGGAACAGAAGAGTGACC
ATGTTAGTCACAGGGTCATTTGGG
ACAGGTTGCGGGAATCCAAAGG
CCTAGGACATCGAGGAACTACCTG
TGGCGAGTTTGAGAAGGTGTGC
TGGCAAAGAAGTGGCAGGAAGAG
ACATACGGTTTAGCTTGGGTGTC
TTTCTCCAGGCTTCCTGAGCTG
GCCATGGATTGCACTTTCGAAGAC
GGTCAAATAGGCCAGGGAAGTCA
C
GCCATCGGTACTCTGAGCTCTATG
TGACGGAATTTGGTGTGGGAAGG
GCCCCCCGTGAAAGACA
CGTCGAAACAGCAGCCCTTA
TGTGGTCCCTTCCAATGCTGTG
TGCTCATGGTTATGGCACTTGGC
CCAGGCAGTCAGATCATCTTCTCG
ATCTCTCAGCTCCACGCCATTG
AGTGGAAGGAAATTTGCGTGTGG
TGGTACAGTCAGAGCCAACCTC
AGGGCAGAATCATCACGAAGTGG
AGGGTCTCGATTGGATGGCAGTA
G
CAGGACCGTGTGGAGCAGATTG
CAGATTGTCCCACTGGTCACAG
TGAGTATGCCTGCCGTGTGAAC
TGCTGCTTACATGTCTCGATCCC

Immunocytochemistry (ICC)
Coverslip seeded cells were rinsed with PBS and fixed in cold acetone,
blocked with 10% normal goat serum and incubated overnight at 4˚C with human
anti-ERβ2 monoclonal antibody (Biorad; Hercules, CA). ERβ2 was conjugated to
Alexa Fluor 488. All coverslips were washed and mounted with Vectashield
containing DAPI. Slides were visualized using DMI 6000 (Leica Microsystems;
Buffalo Grove, IL).
Statistical analysis
Differences among groups were assessed by unpaired t-test and One-Way
Analysis of Variance (One-Way ANOVA) followed by Tukey’s post-hoc test.
Statistical analysis was performed with GraphPad Prism software 4.01.
Quantitative data for experimental analysis are presented as mean values ±
S.E.M with unit value assigned to control and the magnitude of differences
among the samples being expressed relative to the unit value of control.
Results
The cholesterol metabolite 27-OHC increases cell proliferation in PCa
cells
We have previously shown that 27-OHC stimulates cell proliferation in nontumorigenic RWPE-1 cells (Raza et al. 2016). However, the effects of 27-OHC on
proliferation in PCa cells were not determined. Here we show that 27-OHC
stimulates cell proliferation in PCa cells, LNCaP and PC3. Upon 27-OHC
treatment, cell proliferation was increased by ~60% in LNCaP and ~30% in PC3
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compared to their respective controls (Fig 21a,b). To confirm our results, we
performed MTS assay which measures mitochondrial activity of the cells. We
found that 27-OHC also significantly increases metabolic activity of the both cells
(Fig 21c,d). These results suggest that 27-OHC induces cell proliferation in PCa
cells.
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Figure 21: 27-OHC induces cell proliferation in PCa cells. Cell proliferation assay
in LNCaP (a) and PC3 (b) cells demonstrates a significant increase in
proliferation in the presence of 27-OHC. MTS assay shows a significant increase
in cell metabolic activity in the presence of 27-OHC in LNCaP (c) and PC3 (d)
cells. Cells were treated with 1µM 27-OHC. Readings were recorded 48 hours
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after treatment with 27-OHC. Data is expressed as Mean ± S.E.M. ***p<0.001
versus controls.
27-OHC stimulates cell proliferation via ER
Since 27-OHC is a ligand of ER (Umetani and Shaul 2011) and that 27-OHCinduced ER modulation leads to increased cell proliferation in breast cancer cells
(Cruz, Torres, María E. Ramírez, et al. 2010; Nelson et al. 2013; Wu et al. 2013;
Raza et al. 2015), we assessed the importance of ERs in 27-OHC-induced cell
proliferation in PCa cells. We have previously shown that 27-OHC induced cell
proliferation in non-tumorigenic prostate epithelial cells was ER dependent (Raza
et al. 2016). Here, we show that the ER specific inhibitor ICI 182,780 (fulvestrant)
(McKeage et al. 2004) mitigated 27-OHC induced cell proliferation to basal levels
in LNCaP and PC3 cells (Fig 22. a,b). Also, we found that upon concomitant
treatment of 27-OHC and estradiol (E2), the natural agonist of ER (Hall et al.
2001), there was no additive effect in cell proliferation in both cells (Fig 22. a,b).
These results suggest that ER activation is necessary for 27-OHC induced cell
proliferation.
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Figure 22: 27-OHC stimulates cell proliferation via ER. Cell proliferation assay in
LNCaP (a) and PC3 (b) cells demonstrates an attenuation of 27-OHC-induced
cell proliferation with the ER inhibitor ICI 182,780 (Fulvestrant). Cells were
treated with 1µM 27-OHC, 2nM of E2 and 10µM ICI 182,780. Readings were
recorded 48 hours after treatment with 27-OHC. Data is expressed as Mean ±
S.E.M. **p<0.01; ***p<0.001versus controls,
treatment.
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###

p<0.001 versus 27-OHC only

27-OHC selectively up-regulates ERβ expression
Given that 27-OHC stimulates cell proliferation in non-tumorigenic (Raza et al.
2016) as well as PCa cells (Fig. 21a,b) and that 27-OHC is a ligand of both
isoforms of ER, ERα and ERβ (DuSell et al. 2010; Umetani and Shaul 2011), we
determined the extent to which 27-OHC regulates ERα and ERβ protein levels.
We found that 27-OHC had no significant effects on ERα levels, but significantly
up-regulated ERβ levels in the non-tumorigenic RWPE-1 (Fig. 23a-c) and PCa
cells (Fig. 23d-i). When compared to vehicle treated, 27-OHC treated cells exhibit
an increase in ERβ levels by ~250% in RWPE-1 (Fig. 23c), ~100% in LNCaP
(Fig. 23f), and ~50% in PC3 (Fig. 23i). This data suggests a potential
involvement of ERβ in 27-OHC-induced cell proliferation.
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Figure 23: 27-OHC upregulates ERβ expression. Representative western blots
(a) and densitometric analysis showing no significant change in ERα expression
in RWPE-1 (b) and a significant increase in ERβ expression (c) in RWPE-1 cells.
Representative western blots (d) and densitometric analysis showing no
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significant change in ERα expression (e) and a significant increase in ERβ
expression in LNCaP cells. Representative western blots (g) and densitometric
analysis showing no significant change in ERα expression (h) and a significant
increase in ERβ expression in PC3 cells (i). Data is expressed as Mean ± S.E.M.
*p<0.05 versus controls.
27-OHC induces cell proliferation via ERβ
To determine if 27-OHC-induced cell proliferation is due to ERβ specific
activation, we utilized an ERβ specific antagonist PHTPP (Compton et al. 2004).
Upon treatment of the non-tumorigenic and PCa cells with 27-OHC and PHTPP,
PHTPP attenuated 27-OHC-induced cell proliferation to basal levels in all cells
(Fig. 24a-c). This data suggests that ERβ activation is essential for 27-OHCinduced cell proliferation.

82

Figure 24: 27-OHC induces cell proliferation via ERβ. Cell proliferation assay in
RWPE-1 (a), LNCaP (b) and PC3 (c) cells demonstrates attenuation of 27-OHCinduced cell proliferation with PHTPP treatment. Cells were treated with 1µM 27OHC and 10µM PHTPP. Readings were recorded 48 hours after treatments.
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Data is expressed as Mean ± S.E.M. **p<0.01; ***p<0.001 versus controls,
##

p<0.01; ###p<0.001 versus 27-OHC only treatment.
27-OHC reduces cell invasion in PCa but not in non-tumorigenic cells

Cell invasion is a key process by which cancerous cells further tumor progression
and metastasize to distant tissues and organs. Metastatic cells invade healthy
tissue by penetrating through the extracellular matrix (ECM) of healthy cells
(Krakhmal et al. 2015). To investigate the effect of 27-OHC on cell invasion, we
treated cells with 27-OHC and determined the change in cell invasion across the
ECM. We found that upon 27-OHC treatment, cell invasion did not significantly
change in the RWPE-1 cells (Fig. 25a) but significantly decreased in LNCaP and
PC3 cells (Fig. 25b,c). Also, upon PHTPP treatment only, cell invasion significant
decreased in non-tumorigenic RWPE-1 and LNCaP cells but not in PC3 cells
(Fig. 25a-c). Interestingly, PHTPP rescued 27-OHC-induced decrease in cell
invasion of PC3 cells (Fig. 25c). This data suggests that 27-OHC has no effect
on normal prostate but inhibits cell invasion in PCa cells.
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Figure 25: 27-OHC reduces ECM invasion in PCa cells but not in nontumorigenic cells. Cell invasion assay demonstrates that while there was no
change in invasion in RWPE-1 cells treated with 27-OHC (a), a significant
decrease in cell invasion occurred in LNCaP (b) and PC3 (c) cells treated with
27-OHC. Cells were treated with 1µM 27-OHC and 10µM PHTPP. Readings
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were recorded 48 hours after treatment with 27-OHC. Data is expressed as
Mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 versus controls, #p<0.05 versus
27-OHC only treatment.
27-OHC differentially regulates gene expression in non-tumorigenic
and PCa cells.
We determined the extent to which 27-OHC related gene expression is regulated
in normal prostate epithelial RWPE-1 cells and PCa cells (Table 3). We found
that in non-tumorigenic RWPE-1 cells, the expression levels of TFF1 (PS2) and
TMPRSS2 were significantly upregulated by 27-OHC treatment. In LNCaP cells,
CTGF, IGFBP-3, INSIG2, NR1H2 and RXRB was significantly upregulated while
expression of SREBF-1 and TMPRSS2 was significantly down-regulated. In PC3
cells, expression of CBX1, CBX5, CYP27A1, CTGF, FOXA1, GLI2, GLI3, MDM2,
MTA3, OSBP, PTCH1, RXRB and SIRT1 was significantly upregulated and only
SPARC expression was significantly downregulated (Table 3). The sequences
for primers of the significantly regulated genes are presented in Table 2. This
data emphasizes the inherent differences in the cells and the potential genes
regulated by 27-OHC in the different prostate cell lines.
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Table 3: Significantly regulated genes in fold change
Genes

RWPE-1

LNCaP

PC3

CBX1

0.9956

1.0503

1.2222*

CBX5

1.1252

1.0153

1.2895**

CTGF

0.8859

3.5324*

1.4869**

CYP27A1

0.5065

N/E

1.2263**

FOXA1

1.1357

1.1356

1.1534**

GLI2

0.9029

0.8980

1.3012***

GLI3

0.9287

0.9672

1.1714*

IGFBP3

0.9773

2.3619*

1.1511

INSIG2

0.9938

1.1923*

1.1851

MDM2

1.0007

1.0855

1.2051*

MTA3

1.0713

1.1684

1.2135**

NR1H2

0.9437

1.1690*

1.1723

OSBP

1.1333

1.1635

1.2088*

PTCH1

0.9376

1.3609

1.3304*

RXRB

1.1306

1.2035*

1.2004**

SREBF1

0.6093

0.6811*

1.1461

SIRT1

0.9817

1.1805

1.2671*

SPARC

0.9115

1.0014

0.8155***

TFF1

1.8358*

1.3250

1.0190

TMPRSS2

1.4082*

0.8474*

1.1262

N/E denotes not expressed.*p<0.05, **p<0.01, ***p<0.001 versus controls
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27-OHC regulates ERβ2 expression and cellular localization
ERβ is categorized into several isoforms including ERβ1, ERβ2, ERβ4 and ERβ5
which are expressed in the prostate gland (Christoforou et al. 2014) . ERβ1 is the
only functional isoform with a ligand binding domain while the activity of the other
isoforms may depend on ERβ1 expression and isoform ratios (Christoforou et al.
2014). The ERβ1 isoform is the most studied isoform which is known to have a
protective role in prostate cancer while ERβ2 is considered deleterious (M. Chen
et al. 2009; Nelson et al. 2014) and known to correlate with poor prognosis
(Leung et al. 2010). To test whether 27-OHC regulates ERβ2 expression in
prostate cells, we treated cells with 27-OHC and stained for ERβ2. We found that
while ERβ2 is expressed in a punctated fashion in the nucleus and the cytoplasm
in RWPE-1 cells, 27-OHC appeared to increase overall ERβ2 expression (Fig.
26a). In LNCaP cells, we saw no changes in ERβ2 staining intensity (Fig. 26b.)
and in PC3 cells we found that 27-OHC appeared to have no overall effect on
ERβ2 expression (Fig. 26c), however interestingly, stained ERβ2 punctates in
the nucleus decreased when treated with 27-OHC. This data suggests that 27OHC alters the ERβ2 expression and cellular localization depending on the
prostate cell line.
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Figure 26: 27-OHC differentially regulates ERβ2. Representative fluorescence
microscopy images of prostate cells depicting ERβ2 (green) expression &
localization and the nucleus (blue). (a) RWPE-1 cells treated with 27-OHC
showed increased intensity of ERβ2. (b) LNCaP cells treated with 27-OHC
depicted no change in ERβ2 staining intensity and (c) PC3 cells treated with 27OHC demonstrated no change in overall ERβ2 staining intensity, but a decrease
in nuclear ERβ2. All cells were treated with1 µM 27-OHC for 24 hr. Bar, 50µm.
Discussion
This study investigated the role of 27-OHC in PCa cell models. We
demonstrate that 27-OHC induces cell proliferation in PCa cells through ER. We
further show that 27-OHC regulates ERβ expression over ERα. Moreover, we
demonstrate that 27-OHC-induced cell proliferation is dependent on ERβ
activation. We also show that 27-OHC reduces ECM cell invasion in PCa cells
but not in non-tumorigenic cells. Additionally, we found that several genes related
to oxysterol biology were differentially expressed following 27-OHC treatment in
non-tumorigenic and PCa cells. Thus, our data show for the first time a potential
link between 27-OHC and PCa pathogenesis by demonstrating the deleterious
effect of 27-OHC in PCa cellular models.
Previously, we have reported that 27-OHC stimulates cell proliferation in
non-tumorigenic prostate epithelial cells (Raza et al. 2016). Here, we
demonstrate the effect of 27-OHC in PCa cells. Given that cell proliferation is
associated with tumor growth, we measured cell proliferation upon 27-OHC
treatment. We found that 27-OHC significantly increases cell proliferation in
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tumorigenic LNCaP and PC3 cells. Interestingly, the magnitude of 27-OHCinduced cell proliferation in LNCaP is higher than PC3. Also, the magnitude of
27-OHC-induced cell proliferation is higher in RWPE-1 than in LNCaP and PC3.
The three epithelial cell lines have different morphologies, androgen receptor
(AR) status, and depict different stages of PCa pathology. RWPE-1 are nontumorigenic (Bello et al. 1997), LNCaP are androgen sensitive and with low
tumorigenicity (Sato et al. 1997), and PC3 are androgen insensitive and highly
tumorigenic (Kaighn et al. 1979). Taking tumorigenicity of the cells into account, it
appears that 27-OHC increases cell proliferation to a greater magnitude in
prostate cells with low or non-tumorigenic phenotypes versus highly tumorigenic
phenotype. This may suggest the potential role of 27-OHC in early stages of
PCa. Further studies are warranted to study the role of 27-OHC in forming PCa
tumors.
The role of estrogens and estrogen receptors in the context of PCa is
currently being explored. Recently, estrogens have been associated with the
development and progression of PCa (Nelles et al. 2011). Moreover, the
discovery of 27-OHC as a SERM (Umetani and Shaul 2011) adds another
dimension to the growing phenomena of estrogenic actions as well as cholesterol
metabolism role in PCas. Our previous (Raza et al. 2016) and current data
strongly suggest that 27-OHC-induced cell proliferation in non-tumorigenic
prostate cells and in PCa cells is ER dependent. When cells were treated
concomitantly with 27-OHC and the ER inhibitor fulvestrant, proliferation was
substantially attenuated. Given that 27-OHC is known to bind and activate ER
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(Umetani and Shaul 2011; Wu et al. 2013), our results suggest that activation of
ER is required to ensue 27-OHC-induced cell proliferation in PCa cells. This
observation suggests a potential link between 27-OHC, ER and PCa.
It is worth noting that 27-OHC can act as an ER agonist or ER antagonist
depending on the target tissue. For example, 27-OHC activates ER in breast
tissue (Cruz, Torres, María E. Ramírez, et al. 2010; Nelson et al. 2013; Wu et al.
2013) and inhibits the receptor in the vasculature (Umetani et al. 2007b). We
propose an additional novel concept that 27-OHC activates ER signaling in
prostate cells and may thus play a pivotal role in PCa development and
progression.
Furthermore, we demonstrate that 27-OHC-induced cell proliferation in
non-tumorigenic and PCa cells is ERβ dependent. When cells are treated with
the ERβ specific inhibitor PHTPP, 27-OHC-induced cell proliferation is
attenuated, suggesting the 27-OHC-induced ERβ activation as the underlying
factor leading to cell proliferation.
Our results demonstrate that 27-OHC reduces cell invasion in PCa cells
but not in non-tumorigenic cells. The finding that 27-OHC increases cell
proliferation but reduces cell invasion is unexpected, however it is in accordance
with the current environment of diagnosed PCa in which over 90% of PCa
diagnosed are reported to be localized PCas[51,52]. Additionally, it is important
to note that cell invasion and proliferation are two different parameters in cancer.
Moreover, androgen deprivation therapy(ADT) for patients with localized PCa
does not improve survival or delay the use of secondary cancer therapy[53],
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suggesting a potential role of 27-OHC-induced estrogenic signaling in localized
PCa.
Our study measured expressions of genes regulated by 27-OHC in nontumorigenic cells and PCa cells. In non-tumorigenic RWPE-1 cells, we found that
27-OHC treatment upregulated TFF1 (ps2) and TMPRSS2, downstream targets
of ER (Shao et al.) and AR (Lucas et al. 2008), respectively. The upregulation of
these target genes by 27-OHC demonstrates that this oxysterol activates both
ER and AR target genes. This corroborates our earlier report that AR and ER are
necessary to induce cell proliferation in 27-OHC-treated RWPE-1 cells (Raza et
al. 2016). This observation also substantiates the idea that ER and AR activation
simultaneously play a significant role in PCa tumor initiation. For instance, when
Noble rats are concomitantly treated with estradiol and testosterone almost all
rats develop PCa tumors, while only 40% of them develop PCa when treated with
testosterone alone (Bosland et al. 1995; Bosland 2005).
Unlike in RWPE-1 cells, we did not find upregulation of ps2 and
TMPRSS2 genes by 27-OHC in PCa cells. This may be attributed to the fact that
LNCaP has a mutated AR (Veldscholte et al. 1992) and that PC3 does not
express AR (Tai et al. 2011). In PCa cells, we found that the connective tissue
growth actor (CTGF), which plays a vital role in tumorigenesis and wound healing
processes (Jacobson and Cunningham 2012) is upregulated by 27-OHC. Also,
specific to LNCaP, we found a significant upregulation of insulin-like growth
factor binding protein-3 (IGFBP-3) which has been implicated in PCa tumors.

93

IGFBP-3 is an anti-angiogenic and anti-metastatic protein that is upregulated and
localized in the nucleus of PCa tumor cells (Seligson et al. 2013).
Moreover, our results demonstrate that ERβ2 can be regulated by 27OHC. In RWPE-1, the cells which obtained the most increase in cell proliferation
upon 27-OHC treatment, ERβ2 expression increased. Surprisingly while no
change was observed in LNCaP, PC3 demonstrated a reduction in nuclear ERβ2
expression, which corresponds to the decreased cell invasion upon 27-OHC
treatment (Fig 5c). This finding corroborates with the observation that nuclear
ERβ2 abundance is associated with poor PCa prognosis and increased cell
invasion(Leung et al. 2010).
Given the following observations; 27-OHC induced AR transactivation and
increased cell proliferation in an AR dependent manner in RWPE-1 cells & 27OHC does not directly bind to AR (Raza et al. 2016), RWPE-1 is the only cell line
in this study with a wild type AR (Bello et al. 1997) and it is also the only cell line
to show an increase in ERβ2 expression upon 27-OHC treatment. Furthermore,
27-OHC augmented cell proliferation at a greater magnitude in non-tumorigenic
(RWPE-1) compared to low tumorigenic (LNCaP) and highly tumorigenic PCa
cells (PC3). Taken together, we hypothesize that 27-OHC may bind and activate
ERβ inducing downstream AR-ERβ2 crosstalk signaling events leading to
increased cell proliferation which may result into early stages of PCa. Further
studies are warranted to test this hypothesis and determine the relationship
between AR and ERβ2 in the presence of 27-OHC in the context of wildtype AR+
prostate cancers.
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Although there are variations between the both the PCa cells due to their
difference in phenotypes, they have notable similarities. Both having mutated
ARs, LNCaP having a mutated AR for increased androgen sensitivity and PC3
having the mutated AR for decreased androgen sensitivity, hence each cell line
depicts a different stage of PCa. Also, 27-OHC increased proliferation,
decreased cell invasion and increased expression of CTGF in both cell lines,
CTGF is known to play anti-metastatic roles(Chang et al. 2004; Lin et al. 2005).
These results establish a rationale and prelude to the potential role of 27-OHC in
promoting tumor growth in localized prostate cancers.
Altogether, our results demonstrate that 27-OHC induces an increase in
cell proliferation in PCa cells. We also show for the first time that 27-OHCinduced cell proliferation is dependent on ER activation, specifically ERβ, in nontumorigenic and PCa cells. Our study brings new insights into the potential role of
27-OHC-evoked effects on ERs in PCa development and progression. Further
studies delineating underlying mechanisms involved in 27-OHC induced ER-AR
crosstalk in the context of PCa are warranted and may reveal novel therapeutic
avenues to prevent, delay and/or attenuate PCa progression.
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CHAPTER V
CONCLUDING REMARKS AND FUTURE DIRECTIONS
27-OHC and Breast Cancer
We have demonstrated a novel cellular mechanism of action of 27-OHC
which is downstream of ER and contributes to proliferation of ER+ breast cancer
cells. We have shown for the first time that 27-OHC induces an increase in cell
proliferation in ER+ MCF7 cells via the p53-MDM2 axis (Raza et al. 2015).
Further in vivo studies are required to corroborate and apply these findings in a
more clinical model such as breast cancer mouse models. Moreover, while this
study establishes the importance of 27-OHC mediated ER activation in ER+
breast cancer and identifies the p53-MDM2 axis as a potential culprit, many
pieces of this puzzle are missing. For instance, what are the covalent
modifications of p53 and MDM2 that contribute to 27-OHC induced p53 inactivity
or degradation leading to ER+ breast cancer progression? Given that 27-OHC is
an abundant oxysterol in the circulation, do the oxysterol transport proteins play a
role in stimulating ER downstream events leading to ER+ breast cancer
progression? These questions only address part of the missing pieces that are
essential to this study and its potential clinical implication towards ER+ breast
cancers.

96

Another confounding factor to consider and further investigate is that 27OHC is also a ligand for LXR. However, the role of LXR in the etio-pathogenesis
of breast cancer is poorly understood. Nelson et.al showed that in mice with
elevated plasma levels of 27-OHC, there is an increase in metastatic lesions and
epithelial to mesenchymal (EMT) markers (Nelson et al. 2013). Additionally, LXR
activation via LXR agonist GW3965 also increased metastasis and EMT markers
(Nelson et al. 2013). However, the question whether 27-OHC induced breast
cancer metastasis was LXR dependent remains unanswered, since the effect of
27-OHC on breast cancer metastasis in LXR depleted conditions was not tested.
It is important to note that while 27-OHC is a ligand of both ERs and LXRs, 27OHC is a much more efficacious ligand of ERs when compared to LXRs. 27OHC at 1µM binds to ERβ with 90% efficacy and ERα with 50% efficacy (DuSell
et al. 2008; Umetani and Shaul 2011) while 27-OHC gives a maximum of ~2530% efficacy when bound to LXRs at 10µM (Fu et al. 2001; Spencer et al. 2001).
Notably, intracellular levels of 27-OHC in macrophages can be as high as ~40
µM (Fu et al. 2001). Thus, due to 27-OHC induced concentration dependent
activation of ER and LXR, it is important to quantify 27-OHC levels and delineate
downstream ER-specific and LXR-specific signaling mechanisms in the presence
of 27-OHC in ER+ breast cancers.
Moreover, our experiments used exogenous 27-OHC to induce ER
activation leading to cell proliferation, however the endogenous availability of 27OHC may be sufficient to stimulate cell proliferation and ER+ breast cancer
growth. Interestingly, Wu et al. (2013) showed that among ER+ breast cancer
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tissues analyzed, the 27-OHC metabolizing enzyme, CYP7B1 is downregulated
~50% when compared to normal breast tissue, indicating that the loss of
localized 27-OHC metabolism may play a significant role in ER+ breast cancer
tumor growth. Fascinatingly, upon knocking down CYP7B1 in the ER+ breast
cancer cell line MCF7, without the addition of exogenous 27-OHC, cell
proliferation increased by a staggering 78% (Wu et al. 2013). These results
reiterate the deleterious role of tumor localized 27-OHC and perhaps the
potential therapeutic significance of upregulating CYP7B1 in ER+ breast cancer
tumors.
It is important to note that the widely expressed steroid hydroxylase,
CYP7B1 not only metabolizes 27-OHC, but also catabolizes a number of other
steroids such as dehydroepiandrosterone (DHEA), 5-androstene-3β,17β-diol
(Aene-diol), 5α-androstane-3β,17β-diol (3β-Adiol) and 5α-androstane-3α,17β-diol
(Lundqvist and Norlin 2012). The implications of these CYP7B1 related steroids
in the context of ER+ breast cancer are also poorly understood.
Moreover, while we now know that 27-OHC exacerbates ER+ breast
cancer progression, the cellular mechanism of action of 27-OHC is yet to be
determined. The downstream cascade of events following 27-OHC induced ER
activation that evokes ER+ breast cancer growth is poorly comprehended. A few
of the signaling mechanisms involved in 27-OHC induced ER+ breast cancer
growth are GDNF-RET signaling (Wu et al. 2013) and p53-MDM2 axis (Raza et
al. 2015). Additionally, estradiol treated breast cancer cells regulated ~9600
genes while 27-OHC regulated ~2300 genes. Although a significant fraction of
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genes regulated by estradiol and 27-OHC were the same, almost one third of
genes regulated by 27-OHC treatment were not regulated by estradiol treatment
(Nelson et al. 2013). This suggests the importance of studying 27-OHC- specific
regulating mechanisms which may enhance our knowledge about ER+ breast
cancer progression.
27-OHC and Prostate Cancer
To the best of our knowledge, we are the first to report the deleterious role
of 27-OHC in the prostate. We have shown that 27-OHC increases cell
proliferation of non-tumorigenic prostate epithelial cells (RWPE-1) in an ER and
AR dependent manner. Given the fact that there is no evidence to suggest that
27-OHC directly binds and activates AR (Raza et al. 2016), this suggests a
potential crosstalk between ER and AR in the presence of 27-OHC in the
prostate. We have also shown that 27-OHC induces resistance to docetaxel
induced apoptosis (Raza et al. 2016). We have also determined, for the first time,
that 27-OHC induces cell proliferation in PCa cells in an ERβ dependent manner
[unpublished-under peer review]. These findings warrant further experiments
involving in vivo models testing the role of 27-OHC in PCa. Given the observation
that 27-OHC increases cell proliferation in non-tumorigenic prostate epithelial
cells, pending further experiments, it spotlights the tumorigenic potential of 27OHC in the prostate.
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In addition to the aforementioned limitations, these studies address and
focus on only one functional component of PCa, in this case, cell proliferation.
Hyperplasia is one of the beginning stages of PCa and is sustained along with
the progression of the disease until metastasis occurs. Other functional metrics
of prostate cancer growth such as metastasis and tumor growth have not been
fully investigated due to the lack of in vivo resources and experimental models.
Given the fact that our experiments connecting 27-OHC and PCa were the first to
be reported, there is a lack of clinically relevant information that would aid our
research. For instance, currently there is no information available on how much
27-OHC is found in normal versus PCa tissues. While we do know that 27-OHC
levels increase with age, whether this increase also occurs in the prostate is yet
to be determined.
In addition to knowing the availability of 27-OHC in the prostate,
understanding the role of 27-OHC, ER and AR collectively in the context of PCa
may delineate novel mechanisms involved in PCa. This knowledge may provide
insights into the design of innovative and more effective therapeutic targets
compared to the currently prevailing therapeutic regimens.
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Figure 27: Schematic diagram of the role of 27-OHC in hormonal cancers.
Cholesterol is converted to 27-hydroxycholesterol by CYP27A1 which
exacerbates breast cancer proliferation and metastasis by either GDNF-RET
signaling and/or p53-MDM2 axis. 27-hydroxycholesterol also augments prostate
cancer proliferation and potentially metastasis through ER-AR crosstalk
signaling. 27 hydroxycholesterol is metabolized by CYP7B1 to 7α-hydroxylated
sterols.
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Future Directions
The discovery that 27-OHC is an endogenous SERM has generated
multiple avenues of medical research especially in the realm of endocrine related
cancers. However, currently we do not fully comprehend the downstream
signaling cascades involved in 27-OHC induced ER activation in endocrine
related cancers. Furthermore, there is a dearth of information on genome-wide
binding sites of ERs upon 27-OHC induced activation compared to estradiol
mediated ER activation. Given the complexity of nuclear receptor biology and the
tissue dependent promiscuous ligand binding activity of 27-OHC to ER and LXR,
a clearer understanding on how 27-OHC transports and activates receptors in
different tissues at various concentrations is warranted. Also, the crosstalk
signaling, if any, between ER and other nuclear receptors, including AR and
LXR, is yet to be elucidated in the context of hormonal cancers.
Additionally, further studies are warranted to investigate whether 27-OHC
binds to the membrane bound ER, G-protein coupled estrogen receptor, GPER
(GPR30). GPER plays a significant role in propagating the non-genomic pathway
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of ERs and contributes to cancer progression and metastasis (Arias-Pulido et al.
2010; Scaling et al. 2014).
Understanding the mechanisms involved in 27-OHC induced ER activation
endocrine related cancers can aide us in identifying novel therapeutic targets that
can effectively challenge endocrine therapy resistant and recurrent hormonal
cancers.
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